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Metallothionein (MT) is a cysteine rich stress response protein that lacks a signal peptide 
and thus has historically been considered an intracellular protein. However, the presence of MT 
in a variety of extracellular fluids and spaces suggests an additional extracellular role for this 
protein. We have shown that MT released in the extracellular environment can bind to the 
surface of lymphocytes and is a chemoattractant for Jurkat T cells among other cells. 
Additionally, when Jurkat T cells are pre-incubated with MT, there is a decline in the subsequent 
chemotactic response to SDF-1 α.  Jurkat T cells pre-incubation with SDF-1 α can similarly 
block the chemotactic response to MT, suggesting a common interaction of these two proteins 
with SDF-1 α’ s cognate receptor CXCR4. The chemotactic response to MT can be blocked with 
antagonists of G-protein coupled receptors (e.g. cholera toxin and pertussis toxin), AMD3100 
(antagonist of CXCR4) as well inhibitors of the specific GPCR-dependent signaling components 
Arp2/3 and Phospholipase C. The N terminal region of MT is important for interaction with the 
receptor as chemotaxis studies using 10-mer MT peptides showed that two of these peptides 
(MT1-10 and MT4-12) can interfere with the chemotactic response of Jurkat T cells to SDF-1 α. 
MT pre-incubation significantly interfered with the RAW 264.7 cell response to CCL2 as well as 
U937 cell response to RANTES suggesting that the MT chemotactic effect is not limited to one 
specific receptor. Hence, dysregulation and cellular release of MT during toxicant exposure, 
chronic inflammation and autoimmune disease may represent an unexpected immunomodulatory 
danger signal and an opportunity to exploit this phenomenon to develop new avenues for 
therapeutic intervention.  
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Chapter 1: Background and Significance 
 
Metallothionein (MT) is a small molecular weight stress response protein, which is 
highly conserved across species. In mammals, there are four different isoforms of MT present. 
MT-1 and MT-2 are the most abundant isoforms expressed by almost all cell types whereas MT-
3 and MT-4 are more tissue specific [1]. This study will be focused on MT-1 and MT-2 
isoforms, collectively referred to as MT henceforth. MT is constitutively expressed in almost all 
cell types, however it is found at a much higher concentration in tissues such as liver and kidney 
[2]. The expression of MT is up regulated by stressful conditions such as exposure to heavy 
metals, acute phase cytokines, glucocorticoids and oxidative stress [3]. MT’s primary function in 
the intracellular environment is to maintain homeostasis of essential metals such as zinc (Zn) and 
copper (Cu) as well as reduce the toxic effects of metals like cadmium (Cd) and mercury (Hg). 
Additionally, MT can act as a scavenger of reactive oxygen and nitrogen species [4] and regulate 
transcription factor activities such as NFkB and Sp1 [5, 6]. 
Traditionally, MT was considered to be an intracellular protein as it lacks the signal 
peptide sequences or other protein trafficking signals. However, there is evidence documenting 
its presence in extracellular spaces such as milk, bronchoalveolar and prostatic fluids, bile, liver 
sinusoids and serum. MT is also detected in adipocyte cell culture supernatant suggesting that it 
might be selectively secreted from the cells [7]. Extracellular MT plays a significant role on the 
proliferation of lymphocytes and also affects their functions. MT can synergistically increase the 
proliferation of T and B cells when used with Concanavalin A and Lipopolysaccharide 
respectively. [8]. MT plays a role in CD8+ T cell cytotoxic function, CD4+ T cell differentiation, 
and dendritic cell function [9, 10]. 
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Chemotaxis is the directional movement of organisms or cells in response to a chemical 
or stimulus. It is a very important phenomenon observed in several biological processes 
especially those involved in the immune response. Chemotaxis is induced by chemokines, which 
are small molecular weight secreted proteins (about 8-10 kDa). Chemokine receptors are 
typically G- protein coupled receptors (GPCRs), which are seven transmembrane domain 
receptors. Several chemokines are known to bind more than one receptor and chemokine 
receptors can also bind to more than one chemokine [11]. Inflammatory chemokines are a 
chemokine subset that contribute to the recruitment of leukocytes to sites of inflammation tissue 
injury, inflammation as well as tumors [12]. Out of the sixty-one amino acids present in 
mammalian MT, twenty of them are cysteine residues arranged in cys-cys, cys-X-cys and cys-
X3-cys motifs, which are each hallmarks of different classes of chemokines. Two chemokine 
genes map closely to the MT genes in both humans and mice. Clustal Omega alignment of MT 
and chemokine CCL17 shows amino acid sequence similarity, highlighting the structural 
similarities between MT and the chemokines [13].  
Several studies have shown altered levels of MT in different inflammatory and 
autoimmune diseases such as rheumatoid arthritis [14], septic shock and inflammatory bowel 
disease [15], brain inflammation and neurodegenerative disorder [16], diabetes [17] as well as in 
some cancers [18]. The dysregulation of MT during several inflammatory and autoimmune 
diseases, and its structural similarities with chemokines prompted us to investigate its role in 
chemotaxis.  
The focus of this study is to understand the secretion of MT in the extracellular environment 
and its role in chemotaxis along with the related signaling pathways and potential receptor 
involved in MT mediated chemotactic response. The extracellular roles of MT represent a 
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potential “danger signal” that serves as an additional signal to activate the immune system. 
Manipulation of that functionality can alter the progression of an immune response and presents 
a possible opportunity for therapeutic intervention.  
 
1.1 Metallothionein 
	  
1.1.1 History 
	  
The first report on metallothionein was published in 1957 as a cadmium containing 
protein that was isolated from equine renal tissue [19]. The name “metallothionein” was 
conferred to the protein due to high sulphur and metal content [20]. MT was shown to lack 
aromatic amino acids and contain high amount of cysteine residues as indicated by the high 
concentration of sulphur [19, 21]. A study done in Sweden looking at the effects of cadmium 
discovered that MT could be induced by doses of cadmium and the prolonged administration 
leading to MT synthesis developed resistance to acute liver toxicity [22]. Hence, early interest in 
MT was mostly focused on its protein chemistry in relation to metal binding and cadmium- 
related toxicity studies.  The characterization of MT was based on its unique properties such as 
molecular weight of 6-7 kDa, high content of cysteine residues, unique spectroscopic signatures 
associated with metal-thiolate bonds. Classification based on phylogenetic relationships between 
the protein and the nucleotide sequences of different isoforms was revised in 1999 [23].   
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1.1.2 Classes of Metallothionein 
	  
MT is expressed in a large variety of taxonomic groups ranging from prokaryotes to 
eukaryotes. Despite some differences in size and distribution of cysteine residues, there is a 
considerable sequence and structural similarity in MT across different species. In mammals, 56% 
of all MT residues, which include 20 cysteine residues, are conserved. Additionally, the amino- 
terminal of mammalian MT is very similar to MT found in Neurospora crassa highlighting 
similarity across different phyla [24].  
In mammals, there are four different isoforms of MT, which are divided into major and 
minor groups based on expression and abundance. MT-1 and MT-2 belong in the major group 
and are expressed in almost all tissue types, with the highest expression in kidney and liver. 
These two isoforms only differ by a single negative charge and have not been established to be 
functionally different even though their expression profiles are often distinct [25]. The minor 
group includes MT-3, which is primarily expressed in brain and neurons but also in heart, 
kidneys and reproductive organs. MT-4 is the least studied isoform expressed in squamous 
epithelia [26].   
 
1.1.3 Structure of MT 
	  
The primary structure of mammalian MT is made up of 61 to 68 amino acids residues 
(about 7 kDa in weight), out of which 20 are cysteines, 6-8 lysines, 7-10 serines with N- terminal 
acetylmethionine and alanine at the carboxy terminal. The cysteine residues are responsible for 
MT metal binding with the stoichiometry of 7 divalent ions for every 20 cysteines that enables 
MT to form metal thiolate complexes to bind 7-10 g atoms of metal/mol MT in a two-domain 
structure [27].  
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The metal binding domain of MT is folded to give rise to two distinct metal binding 
domains (α and β), which is separated by a non-cysteine containing linker/spacer (Figure 1.1). 
The α domain consisting of amino acids 31-68 located on the C terminal is capable of binding up 
to four divalent metals whereas the β domain contains amino acids 1-30 and can bind 3 divalent 
metals [28, 29]. MT without any metal bound is called the apo-metallothionein form (Apo-MT).  
The binding of metals leads to formation of intramolecular metal linkage that stabilizes MT’s 
secondary structure. Hence, the loss of metals can destabilize the protein making it vulnerable to 
proteolysis [30]. Under normal physiological conditions, MT predominantly binds to zinc (Zn) 
and copper (Cu) in vivo. However, it can also bind to metals such as cadmium (Cd), bismuth 
(Bi), platinum (Pt), silver (Ag), and mercury (Hg) in vitro or under high-administered doses in 
animal [31]. 
As mentioned previously, MT-1 and MT-2 only differ in a single amino acid at position 
11 (aspartate residue) that can be used to separate the two via ion exchange chromatography. 
MT-3 differs from other isoforms of MT due to the presence of a glutamate-rich hexapeptide 
near the C-terminus containing a Cys-Pro-Cys-Pro motif (amino acids 6–9). This fragment is 
considered to confer unique property of MT-3 isoform as a growth inhibitory factor in astrocytes 
of the central nervous system [32, 33].  
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Figure 1.1. MT structure: the protein backbone is arranged as two quasi-globular 
domains that co-ordinate the binding of five cadmium and two zinc atoms. The domains are 
connected by a lysine- lysine dimer. 
 
1.1.4 Regulation of MT 
	  
In rodents, there are four functional MT genes (Mt1, Mt2, Mt3, and Mt4) located on 
chromosome 8. MT is encoded in humans by a family of genes located on chromosome 16q13, 
which includes 17 identified genes and pseudo genes. Of the 17 MT genes, 10 encode functional 
proteins (MT-1a, MT-1b, MT-1e, MT-1f, MT-1g, MT-1h, MT-1x, MT-2a, MT-3, MT-4) and the 
other 7 are classified as non-processed pseudo genes (Mt1c, Mt1d, Mt1i, Mt1j, Mt1k, Mt1l, Mt2b) 
[34].   
Metallothionein genes consist of three exons encoding the α -domain (exon 1) and the β -
domain (exons 2–3). The regulatory mechanisms of the MT-1 and MT-2 isoforms are the best 
recognized so far and it has been shown that these isoforms are induced by several stimuli such 
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as metals, hormones, cytokines, toxic compounds, inflammation and stress [35]. Metals and 
glucocorticoids have been shown to be the most efficient and thus are the most studied inducers 
of MT. The induction of different MT isoforms by these two inducers is variable amongst 
species. For example, in mice both metals and glucocorticoids induce MT-1 and MT-2. In 
humans, metals induce all MT isoforms but glucocorticoids only induce MT-2a and MT-1e [36]. 
Metals such as Zn, Cd, Hg, Cu, Ni can all induce MT, amongst which Cd and Zn are the most 
potent inducers [37].  
The transcriptional regulation of MT by various stimuli is mediated by the different 
regulatory elements. Metal Responsive Elements (MREs) that are present in the promoter region 
of all MT genes regulate the induction of MT by metals [38]. Glucocorticoid response elements 
(GREs), which are present in some MT genes, regulate glucocorticoid-mediated MT induction 
[39]. Similarly, antioxidant response elements (AREs) mediate induction by H2O2, redox-active 
quinones and other oxidants [40]. Additionally, cyclic AMP responsive elements, TPA-
responsive elements, and interferon responsive elements have also been show to regulate the 
induction of some forms of MT [40, 41]. 
The basal expression of MT genes is mediated by basal recognition sequences, which 
include a TATA-box, a GC-box, and at least two basal level enhancer (BLE) sequences, that 
function like classical enhancer elements [42]. The GC boxes act as a binding motif for Sp1 
factors that can synergistically stimulate transcription of MT. General transcription factor II (TF-
II) and upstream stimulatory factor (USF) are other regulatory elements that bind to an upstream 
E box which overlaps with AREs have been shown to be important in basal MT expression in 
both mice and humans. MREs also contribute to basal MT expression via a low level of 
constitutive metal transcription factory 1 (MTF-1) binding [43].  
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As mentioned previously, metals (specifically Zn) are potent inducers of MT. This 
process of induction involves binding of metal regulatory transcription factor-1 (MRF-1) to the 
MRE sequence present in the promoter region of MT.  Non-essential metals like Cd cannot 
directly interact with MRF-1. They increase the intracellular concentration of Zn by displacing 
Zn from MT molecules. The displaced Zn can then bind to MRE sequences and lead to increased 
transcription of MT [44]. Glucocorticoids (GCs) such as cortisol can freely diffuse into the cell 
and can bind to cytosolic GC receptors and become an active transcription factor that binds to 
GRE and increase MT transcription [45]. Reactive oxygen species (ROS) such as H2O2 can lead 
to oxidation of MT releasing the bound Zn metal, which subsequently interacts with MTF-1 and 
induces MT [41] . ROS can also lead to activation of Nrf2 and upstream stimulatory factor 
(USF) that can bind to ARE causing MT induction. Another pathway for induction of MT is via 
cytokines such as IL-6, TNF-α IL-1 α and IL-1 β and their extracellular receptors. IL-6 signaling 
is mediated by signal transducer and activator of transcription 3 (STAT3), which can bind to IL-
6 response elements (IL6RE) located in the 800 bp region upstream of all human and mouse 
MT1 genes between GREs and AREs [46, 47]. Catecholamine, tissue hypoxia, physical exercise 
and hypothermia have also been shown to lead to high expression of MT [48]. Some studies have 
also shown that high glucose levels can induce MT expression in human umbilical vein 
endothelial cells (HUVECs) on stimulation of endothelin receptor-1 (ET1) [49].  
 MT transcription is negatively regulated by Nuclear Factor 1 (NF1), which suppresses 
both the constitutive and metal induced activation of MRF-1 in both humans and mice by 
binding to MRE-c element [50]. Some studies have shown that Zn binding transcription blocker 
ZBTB11 (or PZ120) can inhibit Trans-acting elements. Another mechanism of inhibition of MT 
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expression is by dephosphorylation of transcription factor C/EBPα following PI3K/AKT 
signaling [51].   
 
1.1.5 Expression and localization of MT 
	  
Metallothioneins have been detected in various normal tissues as well as aberrant cells. 
The majority of MT mRNA is translated on free and cytoskeleton- associated polysomes, which 
is responsible for the synthesis of MT that is predominantly found in cytoplasm and nucleus [52, 
53]. MT is also found in other cell organelles such as mitochondria and lysosomes. Simpkins et 
al. reported the presence of MT in mitochondria and it was shown to be transported through the 
outer membrane of mitochondria and regulate permeability of the inner membrane [54]. MT 
found in lysosomes has been shown to protect it from oxidative stress by reducing iron- 
catalyzed intralysosomal peroxidative reactions [55]. MT has also been reported in nuclei of 
different cells even though it lacks the traditional nuclear localization signal and has been shown 
to be translocated there via nuclear pore complex [56]. Some evidence suggest that nuclear 
localization of MT requires oxidation of a cytosolic accessory protein and is a passive diffusion 
process [57]. 
In vitro studies have shown that the majority of MT degradation takes place in the 
lysosome by proteolytic action of cathepsins B and/or L [58, 59]. Additionally, soluble proteases 
in the cytosol can also lead to MT degradation [60]. MT in metal bound state is less susceptible 
to proteolysis and has a longer half-life than apo-MT. Other factors such as pH, which is directly 
associated with the release of metals from MT, has been shown to be important in MT stability 
as well as degradation [61]. The α domain of MT-1 and β domain of MT-2 has been found in 
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liver of zinc treated rats suggesting that different isoforms may have distinctive proteolytic 
degradation pathways [62] .  
Metallothionein has been shown to be present in blood at high concentration following 
exposure to Cd and ranging from 0.51- 1.86 ng of MT per ml in plasma [63]. Additionally MT is 
also present in extracellular spaces as such as serum, milk, urine, bronchoalveolar and prostatic 
fluids, live sinusoids, and pancreatic ducts [7]. MT has also been reported at the sites of 
inflammation and tissue wounding [64-66]. Sabolic et al. suggested that the presence of MT in 
the extracellular environment such as blood might be as a consequence of damaged cells leading 
to leakage through cell membrane or necrosis [67]. However, MT was secreted by adipocytes in 
cell culture as well as in supernatants without cellular damage suggesting that MT can be 
secreted even without necrosis or tissue damage. 
 
1.1.6 Biological roles of MT 
	  
MT in the intracellular environment has been shown to play important roles in cellular 
processes such as metal homeostasis, free radical scavenging, metal detoxification, apoptosis, 
intracellular redox balance, differentiation and proliferation of cells [67-69]. In addition to the 
regulatory and protective role under normal conditions, MT can also play important roles in 
cases of carcinogenesis, invasiveness of cancer and angiogenesis [70, 71]. Hence, MT is seen as 
a multipurpose protein with two faces: roles in normal conditions and as well as in cells under 
pathological stress [69]. Despite having multiple important biological roles, mice lacking MT-1 
and MT-2 proteins as well as transgenic mice overexpressing MT do not show significant 
phenotypic or reproductive abnormalities under normal conditions. However, the significance of 
MT expression in these mice is more obvious under conditions of pathological stress [72]. 
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1.1.6.1 Homeostasis of essential metals 
	  
As mentioned previously, metallothionein has very strong binding capacity for divalent 
essential metals. Hence, MT has been shown to play important roles in homeostasis of essential 
metals Cu and Zn and this phenomenon has been studied widely and also demonstrated in vivo. 
For example, the mice that overexpress MT-1 are more resistant to Zn deficiency than wild type 
mice [73]. MT-1 and MT-2 has been shown to play an important role in protecting mice from Zn 
deficiency as well as Zn toxicity [74].  
Studies have suggested that MT can act as a sensor of localized intracellular redox 
balance and influence redox balance through GSH and the antioxidant properties of Zn. In vitro 
studies have demonstrated that MT can donate Cu to Cu-Zn superoxide dismutase and this 
interaction is under redox control [75, 76]. The role of MT in regulation of Zn has been shown to 
be vast and context dependent.  
 
1.1.6.2 Metal detoxification 
	  
Exposure to various metals leads to overexpression of MT in cells of the kidneys, liver, 
intestine as well as several other cell types [77, 78]. MT induction by low metal dose has been 
shown to confer protection against subsequent high doses. For example, low dose pretreatment 
with Cd or Zn led to development of tolerance to Cd in rats [79]. Additionally, Cd- resistant cell 
lines have been shown to express high levels of MT and these cells are also resistant to toxic 
effects of other metals [80]. Pretreatment of cells with Zn and vitamin A, which are both 
inducers of MT, led to development of tolerance for metal toxicity [81, 82]. The important role 
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of MT in reducing hepatotoxicity of Cd has been demonstrated in vivo in MT null animals as 
well as mice overexpressing MT [83, 84]. Studies have highlighted the role of up regulated MT 
in sequestering Cd ions and diminishing subsequent cytotoxic effects of ROS in Cd treated 
epithelial lung cells [85]. MT null mice have been shown to have severe impairment in kidney 
function. MT knock-out mice developed hypersensitivity to Cd induced bone injury highlighting 
another role of MT in preventing cell and organ toxicity induced by Cd [86]. 
Besides Cd, MT can also confer protection against other metal ions such as lead, 
mercury, copper, and chromate. MT has been shown to protect kidney, liver and lungs against 
arsenic compounds by decreasing the severity of lesions in those organs [87, 88]. A study done 
by Tokar et al. demonstrated that there is an increase in frequency of testicular tumors and 
urinary bladder pre-neoplastic lesions as a result of early life lead exposure in MT knockout mice 
compared to the wildtype [89]. There is an increase in MT synthesis following mercury 
intoxication, which has been shown to be protective against the toxic effects of mercury [90].  
 
	  
1.1.6.3 Regulation of oxidative stress 
	  
Metallothionein is upregulated by hyperoxia, ionizing radiation, exercise, cold exposure, 
tert-butyl hydroperoxide that lead to an increase in oxidative stress suggesting that MT may also 
confer protection against reactive oxygen species (ROS) and nitrogen species (RNS) [91-94]. 
The potential cellular damage caused by free radicals such as ROS and RNS was shown to be 
counterbalanced by the antioxidant property of different MT isoforms [95, 96]. The redox 
property of MT is attributed to the thiolate cluster of the protein and is found to be dependent on 
the stability of zinc thiolate binding [76]. One of the earliest studies to document the antioxidant 
property of MT was carried out in rabbit liver, which showed that MT-1 can scavenge hydroxyl 
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and superoxide radicals effectively [97]. MT can protect against the DNA damaged caused by 
hydroxyl radicals in HL-60 promyelocytic leukemia cells and V79 Chinese Hamster cells [98, 
99]. Additionally, MT can abrogate the tert-butyl hydroperoxide toxicity in mouse embryonic 
fibroblasts [100] and can also protect lymphocytes against UV radiation- induced damage [101]. 
The antioxidant property of MT has been documented in various in vivo studies. MT 
prevented the generation of ROS in a model of acetaminophen-induced liver injury by trapping 
reactive acetaminophen metabolite, N-acetyl-p-benzoquinone imine, which prevented the 
binding of the metabolite to cellular proteins and subsequent nuclear DNA damage [102]. 
Furthermore, MT has been shown to protect against the DNA damage in liver and bone marrow 
of mice with high fat diets [103]. MT’s antioxidant role has been highlighted in diseases such as 
collagen-induced arthritis where it prevented the activation of cyclooxygenase-2 (COX-2) [14]. 
MT was also shown to inhibit the activation of inducible nitric oxide synthase (iNOS) in a model 
of cryogenic brain cortex injury [65, 104]. 
 
1.1.6.4 Roles in apoptosis and proliferation 
	  
Metallothionein’s role in apoptosis has been associated with its free radical scavenging 
and metal binding properties [28]. One of the major regulators of apoptosis is protein p53, whose 
expression is dependent on Zn ion concentration and ROS levels. Hence, some studies have 
shown that MT can regulate the expression and stability of p53. For example, apo-MT can 
directly interact with p53 and sulfhydryl groups mediate this interaction via zinc ion of the p53 
protein. In vitro studies have also shown the modulation of structure of p53 by MT [105]. 
Additionally, reduced expression of MT in cells caused an increase in expression of p53 and 
higher sensitivity towards apoptosis-inducing factors [106]. 
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Several studies have highlighted another important role for MT in the regulation of NF-
kB,	  which is	  a family of highly conserved transcription factors that regulate various cellular 
behaviors such as inflammatory responses, cellular growth and apoptosis [107]. MT can 
positively regulate the activity of NF-kB by interacting with its p50 subunit in murine fibroblasts 
[5], HeLa cells [108] and MCF-7 breast cancer cells [109] . Interestingly, overexpression of MT-
2 has also been documented as a negative regulator of NF-kB in V-H4 hamster mutant cell line 
[110] and mouse embryonic cells [111]. These evidences suggest that MT’s regulation of NF-kB 
is cell type dependent, though the mechanism of this regulation is still unknown.  
High level of MT expression has been reported in late stages of gestational and neonatal 
periods as well as fetal development suggesting that MT plays an important role in cell 
proliferation [112-114]. At sites of active and proliferating tissues such as proliferating hair 
follicles [115] and basal cell layer of epidermis [116], there is an elevated level of MT present. In 
vitro studies have also reported elevated levels of MT during exponential cell growth [117]. 
Despite being a cytosolic protein, MT is detected in the nucleus during proliferation of 
hepatocytes [118]. MT has also been shown to mediate wound healing of skin [119]. 
The differential expression of MT during different stages of cell cycle also supports the 
proliferative role of MT. For example, the highest expression of MT in human colonic HT-29 
cancer cells was found to be in the G1 phase [120]. Additionally, down regulation of MT-2 genes 
in MCF-7 cells led to cell cycle arrest in G1 phase and inhibited cell growth [121]. Other studies 
have shown a positive correlation between MT expression and Proliferating Cell Nuclear 
Antigen (PCNA) in breast cancer [122], lung cancer [123] and soft tissue sarcomas [116] 
highlighting the role of MT in proliferation.  
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1.1.7 MT and the immune response 
	  
 MT can influence proliferation of T cells and B cells. In the presence of Concanavalin A 
(ConA), MT has a synergistic effect on T cell proliferation. Similarly, MT can increase the 
proliferative effect of Lipopolysaccharide (LPS) on B cell proliferation [8]. MT can enhance the 
superoxide anion production by activated macrophages and suppress the ability of macrophages 
to stimulate T cell proliferation [124]. MT also influences the antibody response of a B cell to an 
antigen. MT decreases the anti-ovalbumin production in mice co-immunized with MT and 
ovalbumin compared to ovalbumin alone. This immunosuppression can be reversed by 
administration of UC1MT, monoclonal MT-specific antibody [125].  Additionally, cytotoxic T 
cells co-cultured with MT during initiation and effector phases exhibited suppressed T cell 
function [9]. Recent work has highlighted an important role of MT in intracellular Zn signaling 
during CD4+ T cell activation [126].  
 
1.1.8 MT in diseases 
	  
 The dysregulation of metallothionein has been reported in various disease conditions. 
Several isoforms of MT were shown to be upregulated in tongue tumors and MT-1X was shown 
to be a mediator of tongue cancer resistance-associated protein (TCRP) and the associated 
resistance to cisplatin [127]. MT upregulation in different cases of tumor has been linked with its 
role in proliferation [128] as well as its roles in tumor maturation and differentiation [129].  
Some studies have shown a correlation between MT overexpression and better prognosis in 
colon, bladder, and fibroblastic skin tumors [130, 131]. MT expression has been linked to 
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resistance of mammalian cells to a wide variety of anticancer drugs and also with poor 
chemotherapeutic outcomes [132, 133]. 
 MT has been shown to play an important role in the regulation of different inflammatory 
diseases. Targeted disruptions of the Mt1 and Mt2 genes in mice led to exacerbate chronic 
inflammatory disease and these mice had an increased susceptibility to effects of toxicant [25]. 
The susceptibility to collagen-induced arthritis was shown be decreased by administration of MT 
[14]. Intriguingly, targeted disruptions of the Mt1 and Mt2 genes are also associated with the 
constitutive activation of NF-kB [6], and an enhanced humoral response. Devisscher et al. 
highlighted an important role of MT in the progression of dextran sodium sulfate (DSS)-induced 
inflammatory bowel disease [134].  
 
1.2 Chemokines and Chemokine Receptors 
	  
Chemokines (chemotactic cytokines) are small-secreted proteins about 8-12 kDa that 
direct the movements of different types of cells. There are over 40 chemokines that have been 
identified in humans and the sequence similarities between the chemokines range from 20%- 
90%. Chemokines have a conserved secondary and tertiary structure which is defined by four 
cysteine residues that interact with each other to form a “Greek key” shape. Pro-peptide form of 
chemokines includes a signal peptide sequence about 20 amino acids in length, which gets 
cleaved to mature form after secretion. The mature protein consists of first two cysteines at the 
N-terminal end followed by N loop made up of approximately 10 amino acids. This is followed 
by a single turn helix, three β strands and an α helix at the C terminal which are connected by 
three turns. The third cysteine is located in the center of the molecule and the fourth one is 
located at the C terminal end [135].  
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Chemokines are divided in four main families based on the position of the N-terminal 
cysteine residues. Adjacent cysteine residues characterize the C-C subfamily of chemokines 
whereas the C-X-C subfamily has a variable amino acid residue between the cysteines. Most of 
the chemokines that have been characterized fall under the above mentioned two families. The 
third group of chemokines C-X3-C has two N-terminal cysteine residues separated by three 
variable amino acids and there is only one member of this subfamily characterized in humans 
called CX3CL1 (fractalkine), which possesses a mucin-like glycosylated stalk and exists as a 
soluble or membrane bound chemokine [136]. The fourth subfamily of chemokine is XCL1 
(lymphotactin), which is a lymphocyte-specific chemotactic peptide [137].  
 In humans, the chemokine genes can be mapped to two principle chromosomal sites. 
The first gene cluster is for C-X-C chemokine and is located at 4q13.3. The other gene cluster is 
for C-C chemokines at 17q12 [138].  
 
1.2.1 Chemokine receptors /G-Protein Coupled Receptors 
	  
Chemokine signals are transduced by interaction with chemokine receptors that belong to 
a large family of seven transmembrane domain receptors. These receptors are coupled to 
heterotrimeric GTP-binding proteins and are thus called G-Protein Coupled Receptors (GPCRs). 
There are about 19 chemokine receptors that have been identified and they are designated 
according to the types of chemokine they bind: CXCRs, CCRs, CX3CR, and XCR. The 
chemokine receptors share structural similarities and are made up of short N terminal end 
followed by the seven transmembrane domains comprised of three extracellular loops and three 
intracellular loops and an intracellular C terminus [139]. The N terminus of the receptor is 
important for interaction with the chemokine, which leads to a conformation change of the 
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receptor and downstream signaling events mediated by the receptor’s C terminal domain. Since 
there are only 19 receptors for about 50 chemokines, some receptors recognize more than one 
chemokine. Intriguingly, some chemokines can act as an antagonist for other chemokine and 
their receptors. For example, CXCL9, 10 and 11 which bind to CXCR3 are natural antagonists 
for CCR3, while CCL11 that binds to CCR3, is a natural antagonist for CXCR3 [140, 141].  
There are five additional atypical chemokine receptors, CXCR7, CCBP2, CCRL1, 
CCRL2, and DARC. These receptors can bind to a large number of chemokine ligands but fail to 
transduce the full spectrum of chemokine receptor signaling. Their main function is to act as a 
chemokine scavenger or decoy receptor/transporter. Duffy Antigen Chemokine Receptor 
(DARC) is a classic example of atypical chemokine receptor that is expressed by erythrocytes 
and venular endothelial cells that can function as a chemokine sink. Mantovani et al. and Ulvmar 
et al. have provided an in-depth review on these atypical chemokine receptors [142, 143].  
 
1.2.2 Chemokines and the immune response 
	  
Chemokines can be divided into two main categories based on their function: homeostatic 
and inflammatory. Homeostatic chemokines are expressed constitutively in cells and tissues in 
the absence of a triggering stimulus. Some of the examples of homeostatic chemokines are 
CCL14, CCL19, CCL20, CCL21, CCL25, CCL27, and CXCL13.  Inflammatory chemokines 
such as CCL2, CXCL2, CCL14, CCL19, CCL20, CCL21, CCL25, CCL27, CXCL12 and 
CXCL13 are expressed under pathological conditions and play an important role in the 
inflammatory response. This classification is not strict as some chemokines such as CCL20 can 
function as a homeostatic as well as inflammatory chemokine [138].  
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 Chemokines can influence T cell differentiation by either direct interaction on T cells or 
by altering antigen presenting cells or cytokine secretion in the T cell’s microenvironment. For 
example, the upregulation of CXCR4 on CD4+ T cells was associated with increased cytokine 
secretion and differentiation to helper T cells (Th) [144]. There are subsets of CD4+ T cells that 
are associated with specific chemokine receptors and have been shown to play a role in various 
immune responses. Th1 cells express CCR5 and CXCR3; Th2 cells express CCR4 and CCR8 
[145, 146]; Th17 express CCR6 and T regulatory cells (Tregs) express CCR4 and CCR6 [147-
149]. Central memory T cells (TCM) are characterized by expression of chemokine receptor 
CCR7 and the adhesion molecules CD26L or α4β7, which are responsible for continuous 
circulation through the secondary lymphoid tissues [150]. Follicular helper T cell (TFH) expresses 
CXCR5 that is essential for homing to the B cell compartment [151]. These specific subsets can 
respond to chemokine ligands that are secreted by antigen presenting cells or immunomodulatory 
cells and are responsible for direct migration of these cells [145].  
 Some chemokines are localized within specific tissues. CCL27 is one of the most 
studied chemokines in the skin. CCL27 binds to its receptor CCR10 that is expressed by 
melanocytes and has been shown to participate in skin development [152]. This chemokine 
receptor axis also plays important role in recruitment of a subset of T cells that express cutaneous 
lymphocyte antigen [153]. CCL25 and CCL28 are well known mucosal chemokines that recruit 
T cells to the lamina propria of intestine and have been shown to play an important role in 
pathogenesis of Crohn’s disease and ulcerative colitis [154, 155]. CXCL14 and CXCL17 are two 
other chemokines that are expressed in mucosal sites such as taste buds but have not been very 
well studied [156, 157]. 
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 Chemokines are highly expressed at sites of lymphoid development and are thus shown 
to play important roles in T cell development. CCL25-CCR9 axis is an example of chemokine 
receptor axis that is involved in T cells development in the thymus [158]. Chemokines such as 
CXCR4, CCR7 and CCR9 participate in the seeding of the thymus rudiment by hematopoietic 
bone marrow precursors [159]. CCR9 is also required for progression of thymocytes from 
CD4+CD8+ stage to mature CD4+ thymocytes during the T cell maturation [160]. 
 Chemokines have been shown to be involved in variety of cellular processes besides 
chemotaxis. C-X-C chemokines that have characteristic glutamate-leucine-arginine (ELR) motif 
at the N terminal end have been shown to be important for wound repair and angiogenesis [161]. 
Chemokines can influence macrophage plasticity and their interaction with lymphocytes [162]. 
 
1.2.3 Role of chemokines in inflammation 
	  
 The inflammatory response involves recruitment of circulating lymphocytes to sites of 
inflammation by extravasation and chemotaxis. This process is mediated by “inside-out” 
signaling initiated by intracellular signals that activate the ligand binding functions of integrins. 
Additionally, the interaction between integrins and their various ligands induces “outside-in” 
signals across the membrane, which allows the cell to sense the extracellular environment and 
respond accordingly [163]. The leucocytes adhere to luminal side of blood vessels, which is 
followed by transendothelial migration and subsequent chemotaxis. After crossing the 
endothelial barrier, leucocytes chemotax in response to a chemokine gradient that results in 
specific localization of leucocytes within the tissue [164]. The binding of chemokine to receptors 
leads to neutralization and endocytosis of the engaged receptor allowing recycling and de novo 
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chemokine sensing. Additionally, at the site of highest chemokine gradient there can be 
homologous desensitization leading to decreased leucocyte migration and relocation. [165].  
 As mentioned previously, there is a subset of chemokines (inflammatory chemokines) 
that play an important role in the inflammatory response. These chemokines have a broad range 
of cell selectivity and act on cells of both adaptive and innate immune response. Neutrophils are 
the one of the first responders after an acute inflammation caused by agents such as bacteria, 
injury, etc. CXCL8 (IL8) and its receptors CXCR1/2 are involved in recruitment of neutrophils 
at the site of inflammation. If neutrophils are unable to resolve the acute inflammation, it 
perpetuated into the chronic stages, which is mediated by infiltrating macrophages and 
lymphocytes. CCL2 and its family of chemokine and receptors are involved in the regulation of 
macrophage infiltration [166].  
 
1.2.4 Chemokines and diseases  
	  
As previously discussed chemokines play a significant role in the inflammatory response. 
Hence, chemokines and their receptors are implicated in several inflammatory diseases. C-C 
chemokines such as CCL2, CCL3, and CCL5 are upregulated in the joints of patients with 
Rheumatoid Arthritis, which leads to recruitment of monocytes and T cells into synovial tissues. 
In cases of asthma, CCL11 and its receptor CCR3 are responsible for recruitment of eosinophils 
to the lung. Psoriasis, which is another example of inflammatory disease, involves T cells 
expressing CCR4 that are recruited by cutaneous cells producing CCL17 and CCL22 [167]. 
CCL20-CCR6 and CCL25-CCR9 are examples of chemokine receptor axes that have been 
shown to be important in pathogenesis of inflammatory bowel diseases [168]. There are multiple 
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C-C chemokines as well as CXCL12 that have been implicated in allergic diseases as well as 
asthma mostly due to their ability to recruit eosinophils, T cells and monocytes to regions of 
inflammation [169].   
Several chemokines have been implicated in patients with multiple sclerosis (MS). Some 
studies showed that CCR7 plays a role in movement of CD4+ T cells out of tissues and into the 
lymphatic organs [170]. Patients with MS had lower level of CCL2 expression in the 
cerebrospinal fluid, which could be due to interaction with circulating mononuclear cells that 
express CCR2, the main receptor for the chemokine [171]. Other chemokines such as CXCL10, 
CCL3, CCL4, CCL5 and CCL8 are present at the site of multiple sclerosis lesions, which are 
suggested to regulate the movement of monocytes and macrophages into the lesions [172]. 
Cytokines and chemokines have been shown to play an important role in insulin 
resistance. CCL2 activates the adipocytes that express CCR2 leading to an increased expression 
of inflammatory genes and impaired uptake of insulin- dependent glucose [173]. Obese mice 
with a deficiency in CCR2 were found to have improved insulin resistance highlighting 
important role of CCL2 in metabolic syndrome [172]. 
 
1.2.5 Chemokines and cancer 
	  
Tumors are made up of heterogeneous mixture of stromal cells such as fibroblasts and 
endothelial cells and inflammatory cells such as neutrophils, macrophages, and lymphocytes 
[174]. All of these cells contribute to the chemokine milieu at the tumor sites and the chemokines 
can regulate the influx of different types of cells to and from the site. The role of chemokine at 
tumor site has been shown to be different depending upon the type of tumor. Studies have shown 
that chemokines may regulate inflammation within the tumors and can also affect tumorogenesis 
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[175]. For example in ovarian cancer, CCL2 and CCL5 are localized within the tumors and are 
correlated with presence of lymphocytes and macrophages in the region [176]. CCL2 was shown 
to shift the cytokine response to Th2-polarization and CCL5 was associated with infiltration of 
CD8+ T cells [177, 178]. Some studies have reported that in cases of ovarian cancer, tumor-
infiltrating macrophages secrete CCL22 resulting in chemotaxis of CD4+CD25+CD3+ Tregs, 
which express CCR4 (receptor for CCL22). These infiltrating Tregs inhibit the activity of tumor 
specific cytotoxic T cells and lead to suppression of anti-tumor response [179]. Additionally 
CCL2, CCL4, CCL5 and CXCL12 may facilitate tumor progression by inducing matrix 
metalloproteinases (MMPs) in different cases of cancer [178, 180].   
Chemokines such as CXCL1, CXCL2, CXCL3 and CXCL8 have been reported to 
contribute to tumor growth by acting as autocrine growth factors in cases of melanoma and other 
cancers [181, 182]. As mentioned previously, ELR chemokines can regulate angiogenesis and 
these chemokines have been shown to influence chemotaxis of endothelial cells and regulate 
angiogenesis in tumor microenvironment [183]. On the contrary, chemokines CXCL9 and 
CXCL10 can inhibit angiogenesis and tumor progression in cases of human lung cancer [184].  
CXCR4-CXCL12 axis is one of the most well studied chemokine in cancer metastasis 
and has been implicated in more than 23 different human malignancies including breast cancer, 
ovarian cancer, melanoma, prostate cancer, etc. [185]. This will be discussed in detail in the 
Chapter 4. CCR7 is expressed by breast cancer cell lines and melanoma cell lines [186]. CCR7 is 
also expressed in different types of cancer such as breast, gastric, non-small cell lung, etc. and 
the expression is correlated with nodal metastasis and poor clinical outcome [187, 188]. 
Additionally, the overexpression of CCR7 in B16 murine melanoma cells increased the 
metastatic property by around 700-fold and was blocked by anti CCL21 (ligand for CCR7) 
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[189]. Another chemokine-receptor axis that has been implicated in melanoma is CCR10- 
CCL27. CCR10 was detected at moderate to high levels in 10 of 13 primary melanomas. The 
administration of neutralizing anti- CCL27 antibodies in B16 melanoma cells blocked the 
formation of tumors [190]. CCR10 has also been shown to be expressed by certain forms of 
malignant T cell lymphomas [191].  
 
1.3 Danger Signals 
	  
Matzinger et al. first postulated the Danger hypothesis in 1994 to describe the immune 
response to substances that cause damage and not just those that are recognized as foreign. The 
damage-associated molecular patterns (DAMPs) consist of molecules that are produced or 
secreted by cells that can act as a co-stimulatory signal to initiate the immune response [192]. 
The danger signals can be divided into two main classes: endogenous signals and exogenous 
signals. Endogenous signals are produced and released by the tissues undergoing stress, damage 
or abnormal death and exogenous signals are produced by pathogens. Some of the examples of 
endogenous danger signals are heat shock proteins, nucleotides, reactive oxygen intermediates, 
extracellular matrix breakdown products, neuromediators and cytokines. Some of these danger 
signals are constitutive whereas others are induced under the favorable conditions. They can be 
both intracellular as well as secreted [193]. 
CD40 ligand (CD40-L) was one of the first danger signals to be characterized. Under 
normal conditions, CD-40L expressed on activated T cells facilitates the communication with B 
cells and dendritic cells (DCs). However in tissues with injury, the CD-40L expressed by 
platelets can act as a stimulator for DC to initiate an immune response [194]. Cytokines Tumor 
Necrosis Factor α (TNF-α) and Interleukin 1- β (IL-1 β) stimulated in response to inflammation 
	   25	  
act as a danger signal at sites of tissue injury. Type-I interferons that are induced as a result of 
viral infections such as influenza virus or treatment with a synthetic mimic of double stranded 
RNA can activate resting DCs [195]. Another example of inducible danger signals are the 
reactive oxygen species released by metabolically stressed cells that activate NF-kB [196]. Some 
components of extracellular matrix modified by activation of proteases during injury or 
inflammation can also act as a danger signal and activate macrophages and DCs [193]. Heat 
shock proteins secreted under specific conditions can also act as danger signals (discussed in the 
following section). 
 
1.3.1 Heat shock proteins 
	  
Heat shock protein (HSPs) are a family of highly conserved proteins that are highly play 
important roles in protein folding, transport and protection from stressful conditions. HSPs are 
transcriptionally regulated by heat shock factors (HSFs) and are up regulated in response to 
variety of environmental stressors such as starvation, hypoxia, infection, inflammation, exposure 
to toxins, etc. [197]. HSPs are ubiquitous, found in almost all cellular compartments and the 
nomenclature is based on the size of the protein. There are six major families of HSPs: Hsp100, 
Hsp90, Hsp70, Hsp60, Hsp40 and the small HSPs [198].  In mammals, HSPs can function as 
molecular chaperones and are responsible for correct folding, assembly and translocation of 
intracellular proteins. During stressful conditions, HSPs can function as kinetic traps for non-
native proteins as soluble folded intermediates in a refolding competent state [199]. Hsp70 is one 
of the most well studied heat shock proteins and has been shown to play an important role in 
protection against different cell stressors such as heat shock, anoxia, heavy metals, and arsenite 
and ethanol toxicity. The eukaryotic Hsp70 multigene family encodes different chaperones 
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including the constitutively expressed hsc70, the major inducible Hsp70, the inducible Hsp72, 
the glucose-regulated grp78/BiP, and the mitochondrial P75 [200].  
 Heat shock proteins secreted by necrotic cells can act as a danger signal and activate DCs 
and macrophages [201]. Heat shock proteins can bind to a variety of receptors. For example 
Gp96, which induces maturation of DCs, can bind to low- density lipoprotein receptor CD91 as 
well as scavenger receptor CD36 [202, 203]. Hsp60 and Hsp70 are recognized by Toll-like 
receptor (TLR) family such as TLR co-receptor CD14 [204].  
 HSF-1, which was originally identified as a transcriptional activator of HSP genes, has 
been implicated in other functional regulation in eukaryotes. For example in HSF-1 deficient 
mice there was impairment in extra embryonic development and ubiquitin proteolytic pathway 
[205]. HSF-1can also repress cytokine and acute response genes such as tumor necrosis factor α, 
pro- interleukin 1β, c-fos, etc [206, 207]. Interestingly, Nagarsekar et al. have shown that the 
CXC family of chemokines can be described as a new class of stress response genes as there is a 
consistent correlation between the expression of HSP and CXC chemokines in vitro as well as in 
vivo [205]. The completion of this study will lead to a better understanding of MT mediated 
chemotactic response in the extracellular environment that may represent a potential “danger 
signal” that serves as an additional signal to activate the immune system. 
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Chapter 2:  Methods and Materials 
	  
Buffer Recipes:  
 
6x Loading Buffer  
 7 ml 4x Tris-Cl/SDS, pH 6.8 
 3.8 g Glycerol 
 1 g SDS 
 0.93 g DTT 
 1.2 mg bromophenol blue 
 add H2O to 10 ml 
 Aliquot and store up to one year at -80 °C 
 
Running Buffer 
 25 mM Tris Base 
 191 mM Glycine 
 5 ml 20% SDS  
 Bring to 1 L with H2O and store up to one year at room temperature (RT) 
 
Western Blot Blocking Buffer 
 10% non-fat milk 
 2% BSA 
 In TBS-T, prepare immediately before use 
 
Western Blot Developing Buffer 
 100 mM Tris Base 
 10 mM MgCl2 
 100 mM NaCl 
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 Bring to 1 L with H2O, adjust to pH 9.5 
 Store up to one year at RT 
 
Western Blot Substrate Buffer 
2.5 ml Nitroblue tetrazolium chloride (10x NBT 1 mg/ml in Western Blot Developing 
Buffer) 
25 µl 1000x 5-Bromo-4-chloro-3-indolyl phosphate (50 mg/ml) in DMSO 
Bring to 25 ml with Western Blot Developing Buffer, use immediately 
  
ELISA Coating Buffer 
 0.785 g Sodium carbonate 
 1.465 g Sodium bicarbonate 
 0.2 g Sodium Azide 
 Bring to 500 ml with H2O, adjust to pH 9.72 
 Store up to one year at RT 
 
ELISA Binding Buffer  
 0.25% BSA in PBS-T 
 Store up to one week at 4 °C 
 
ELISA Blocking Buffer 
 2% BSA in ELISA Binding Buffer 
 Prepare immediately before use 
 
FACS Buffer 
 0.1% NaN3 
 5% FBS 
 in PBS, store at 4 °C for up to one week 
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ACK (Ammonium-Chloride-Potassium) Lysis Buffer 
 150 mM NH4Cl 
 10 mM KHCO3 
 0.1 mM Na2EDTA 
 pH to 7.4 
 Filter sterilize, store up to one year at RT 
 
Lysis Buffer: 
 20 mM Tris-HCl 
 150 mM NaCl 
 2 mM EDTA 
 1 mM Na3PO4 
 1 mM PMSF 
 5 mM NaF 
 1% NP-40 
Store at -20 °C for up to 6 months 
 
 
2.1 Tissue Culture 
	  
The human Jurkat T lymphocyte cell line (ATCC TIB-152) was cultured at 37 °C with 
5% CO2 in RPMI -1640 (Sigma, Cat# R8758) supplemented with 10% heat inactivated Fetal 
Bovine Serum (Atlanta Biologicals, Cat# S11550), 25 mM HEPES buffer (Corning, Cat# 25-
060-Cl), 4 mM L-Glutamine (Sigma, Cat# 56-58-9), 1% penicillin/streptomycin (Cellgro, Cat# 
30-002-CI), and 1 mM Sodium Pyruvate (MP Biomedicals, Cat# 1682049). The cells were 
passed every other day to maintain the concentration below 106 cells / ml by aspirating spent 
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media with cells using sterile technique and replenishing with fresh media. U937 cells, which 
are monocyte cells, were cultured using the same cell culture technique. 
The macrophage cell line, RAW264.7 (ATCC TIB-71), was cultured at 37 °C with 5% 
CO2 in RPMI -1640 supplemented with 10% heat inactivated Fetal Bovine Serum, 25 mM 
HEPES buffer, 4 mM L-Glutamine and 1% penicillin/streptomycin. RAW macrophages are an 
adherent cell line. Hence, the cells were dislodged from the bottom of the flask by using cell 
scraper (Fisherbrand, Cat# 08-100-241) before each passage to maintain the cell density below 
106/ ml.  
MDA-MB-231 cells (ATCC® HTB-26™), an epithelial breast cancer cell line, was 
cultured at 37 °C with 5% CO2 in DMEM (Gibco, Cat# 11965-084) supplemented with 10% 
heat inactivated Fetal Bovine Serum, 4 mM L-Glutamine and 1% penicillin/streptomycin. The 
cell concentration was maintained below 106 cells / ml by passages at least every 48 hours. 
Since MDA-MB-231 cells are adherent, they were dislodged from the bottom of the flask by 
using cell scraper (Fisherbrand, Cat# 08-100-241) before each passage.  
 
2.2 Primary splenocytes isolation and culture 
	  
Mice were euthanized by CO2 asphyxiation and then the spleen was collected after 
dissection using sterile technique. A single cell suspension was made by grinding the spleen 
using frosted glass slides (Corning, Cat #2948). The suspension was then put through a 40 µm 
cell strainer (Fisherbrand, Cat# 22363547) and the red blood cells were lysed using ACK lysis 
buffer. The cells were resuspended in splenocyte media (DMEM supplemented with 10% heat 
inactivated Fetal Bovine Serum, 4 mM L-Glutamine and 1% penicillin/streptomycin, 1% non 
essential amino acids, 2% sodium bicarbonate and 1% sodium pyruvate). 
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2.3 Cadmium treatment for MT expression 
	  
Jurkat T cells (106/ ml) were treated with cadmium chloride (0- 20 µM) in cell culture 
media. The cells were plated in 24- well tissue culture plate (Falcon, Cat# 353047) overnight at 
37 °C with 5% CO2. Cell viability was determined by trypan blue exclusion after cadmium 
treatment.  
 
2.4 Exosome isolation 
	  
Jurkat T cells were treated with or without cadmium in media with exosome-depleted 
FBS (Gibco, Cat# A27208-03) as described in Section 2.3. Following cadmium treatment, 
exosomes were isolated from the cell culture media using Exosome Isolation reagent (Thermo 
Fisher, Cat# 4478359). After isolation, the exosomes were lysed (or not) using RIPA buffer (25 
mM Tris-HCL, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS, 1X Protease 
Inhibitor). Then they were analyzed for heat shock protein70 (Hsp70) and MT by silver stain and 
Western Blot.  
 
2.5 Chemotaxis assays 
2.5.1 Boyden Chamber 
	  
Chemoattractants (25 µl) were reconstituted in complete media and added to the bottom 
wells of the Boyden chamber. Media alone was used as a negative control. Neuroprobe 
membranes optimized for pore size according to the cells of interest were placed on top of the 
chemoattractants. For Jurkat T cells and RAW macrophages the membranes with 5 µm pore size 
(Neuro Probe, Cat #PFB5) were used. For MDA-MB-231 and U937 cells, membrane with 8 µm 
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pore size (Neuro Probe, Cat# PFB8) and for splenocytes, membranes with 3 µm pore size (Neuro 
Probe, Cat# PFB3) were used. After chamber assembly, 50 µl of the cell suspension (2x 106/ ml) 
was added to the wells of upper chamber. The Boyden chamber was then incubated at 37 °C with 
5% CO2. After incubation, the chamber was disassembled, the cells were scraped off of the top 
of the membrane and the migrated cells on the lower side of the membrane were stained using 
Hema 3 stain set (Protocol, Cat# 122-911) and were counted under the light microscope.  
 
2.5.2 ECIS/Taxis 
	  
These assays were performed as described by Pietrosimone et al. [208]. Briefly, ECIS/ 
Taxis electrodes (Applied Biophysics, custom arrays) were treated with 10 mM cysteine for 15 
minutes, washed and then filled with 0.5% agarose made in complete RPMI media. Two wells 
were cut in the agarose on either side of the target electrode with 14 gauge cannulae 
approximately 2 mm apart. Chemoattractants were placed in one well and cells of interest were 
placed in the opposing well. The electrodes were connected to the ECIS array holder in a 
humidified cell incubator at 37 °C with 5% CO2. The ECISθ software was used to record the 
increase in resistance over 24-48 hours at 4,000 hertz. 
 
2.6 Protein detection 
	  
2.6.1 Bicinchoninic Acid (BCA) Protein Assay for protein quantification 
	  
Bovine Serum Albumin (BSA) diluted in PBS ranging from 2,000 µg/ml to 1.95 µg/ml 
was used to create a standard curve. 10 µl of the standard, or unknown protein sample diluted in 
PBS, were loaded in triplicate to a clear, flat bottom 96- well plate (Greiner bio-one, cat 
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#655101). The working reagent was prepared by combining 1 Part reagent B with 50 parts 
Reagent A (Pierce, Cat# 23225). 200 µl of the working reagent was added to each well and the 
plate was incubated at 37 °C for 30 minutes. The absorbance reading was measured at 560 nm on 
the Molecular Devices, Spectra Max M2 96-well plate reader. The unknown protein sample 
concentration was then extrapolated from the standard curve. 
 
2.6.2 SDS PAGE 
	  
The gel was prepared according to following recipe. 
 Separating Gel 15% (10ml)  Stacking Gel 6% (5ml) 
1.5 M Tris-HCl  2.5 ml  - 
0.5 M Tris-HCl - 1.25 ml 
40% Acrylamide 3.75 ml 750 µl 
Water 3.56 ml 2.9 ml 
10 % Sodium Dodecyl Sulfate 100 µl 50 µl 
10% Ammonium Per Sulfate 100 µl 50 µl 
TEMED 10 µl 5 µl 
**Prepare ammonium per sulfate fresh for each use 
After setting up the gel apparatus, the separating gel was poured first to approximately 1 
mm below the bottom of the comb. Then 1 ml water saturated 1- butanol was added to get rid of 
bubbles and the gel was left to solidify for 1 hour. After solidification, the butanol layer was 
poured off and the stacking gel was added. Immediately combs were inserted in to the stacking 
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gel without introducing any bubbles. The gel was left to solidify for another hour. The gel was 
either used immediately or stored up to 24 hours in wet paper towel and saran wrap at 4 °C.  
After stimulation or other experimental treatment, protein quantification was done by 
BCA assay as described in Section 2.6.1. Then equal total protein concentration of samples was 
diluted in loading buffer to 1X. The samples were boiled in a heat block at 95°C for 5 minutes. 
Then the samples were loaded onto the 15% gel with gel loading pipette tips. The gel was run in 
1X running buffer at 120 volts for an hour (or until the dye reached the bottom of the gel). 
 
2.6.3 Silver Stain 
	  
  After electrophoretic separation of proteins on 15% SDS PAGE gel, they were then 
subjected to silver stain for protein detection. Briefly, the gel was fixed in 150 ml 50% methanol 
+ 5% acetic acid for 20 minutes, followed by 50% methanol for 10 minutes. This was followed 
by sensitization with 0.02% sodium thiosulfate. The gel was then submerged in 0.1% silver 
nitrate with 0.08% formalin (37%) for 20 minutes to allow the silver reaction, which was then 
visualized by developing solution made up of 2% sodium carbonate with 0.04% formalin. After 
the desired intensity of protein band was developed, the reaction was then stopped using 5% 
acetic acid treatment for 10 minutes. For long-term storage, the gel incubated in preserving 
solution made with 10% glycerol for 20 minutes.  
2.6.4 Western Blot 
	  
Following the electrophoretic separation of proteins on SDS-PAGE gel, western blot was 
used to detect MT or Hsp70. Briefly, gel was transferred on to PVDF membrane of the iBlot™ 
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system (iBlot Transfer Stack: ThermoFisher Scientific, Cat. #IB401002) and it was assembled 
according to manufacturer’s instructions. After performing the transfer, the membrane was 
removed from the iBlot™ and immediately place in blocking buffer and incubated for at least 
one hour at RT with gentle shaking.  A 1:500 dilution of UC1MT antibody or anti- Hsp70 
antibody in TBS-T was made and added to dish for a final concentration of 1:1000 UC1MT in 
5% milk, 1% BSA in TBS-T. The primary antibody was incubated overnight at 4 °C with gentle 
shaking. Next day, membrane was washed and stained with secondary antibody; 1:1000 alkaline 
phosphatase conjugated goat anti-mouse Ig (H+L) in TBS-T and incubated for one hour at RT 
with gentle shaking. The membrane was then washed three times and developed in 25 ml 
substrate buffer until clear bands were observed. Water was added to stop the reaction.  
 
2.7 MT binding to the surface of Jurkat T cells 
	  
Jurkat T cells  (5 x 105 / condition) were treated with CdCl2 as described in Section 2.3. 
The cells were then washed with FACS buffer and incubated with 1.25 µg UC1MT-Alexa Fluor 
647 or MOPC21- Alexa Fluor 647 (isotype control) diluted in 50 µl FACS buffer for 45 minutes 
on ice in the dark. After incubation the cells were washed and suspended in 200 µl FACS Buffer 
in 12x75 mm tubes and fixed with 4% paraformaldehyde. The presence of MT on the surface of 
cells was detected using the BD Biosciences LSRFortessa X-20 Cell Analyzer, and analyzed 
using FlowJo Software. 
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2.8 Measurement of chemokine by ELISA  
	  
Immulon 2HB plate was coated with 2 µg/ml of anti SDF-1 α or UC1MT and 
incubated overnight at 4°C. Wells were washed with PBST and blocked with 2% BSA in PBS 
for one hour at RT. Wells were washed, coated with dilutions of recombinant SDF-1 α or MT, 
and incubated for 2 hours at RT. Plate was washed and incubated with 1 µg/ml secondary 
antibody conjugated with biotin for 2 hours at RT. Plate was washed and incubated with 
streptavidin-HRP for 20 minutes at RT. After a final wash, substrate (R & D, Cat# DY999) was 
added and incubated for 20 minutes at RT before addition of stop solution (2N H2SO4) and 
OD450 measured in Spectramax plate reader.  
 
2.9 Competition ELISA to measure MT concentration 
	  
Immulon 2HB plate was coated with 500 ng/ml of MT and incubated overnight at 4°C. Wells 
were washed with PBST and blocked with 2% BSA in PBS for one hour at RT. MT standards 
were prepared according to the following template:  
Standard (in 
triplicate) Dilution Units 
 
1 10000 ng MT/well 
2 1000 ng MT/well 
3 100 ng MT/well 
4 10 ng MT/well 
5 1 ng MT/well 
6 0.1 ng MT/well 
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The MT standards along with the unknown samples were mixed with 500 ng/ml UC1MT. Wells 
were washed, coated with dilutions of MT standards and unknowns and incubated for 2 hours at 
RT. Plate was washed and incubated with 1 µg/ml secondary antibody conjugated with biotin 
for 1 hour at RT. Plate was washed and incubated with streptavidin-HRP for 20 minutes at RT. 
After a final wash, substrate (R & D, Cat# DY999) was added and incubated for 20 minutes at 
RT before addition of stop solution (2N H2SO4) and OD450 measured in Spectramax plate 
reader.  
 
2.10 Measurement of ERK phosphorylation 
	  
Jurkat T cells (5 x105 / condition) were stimulated with 12.5 nM SDF-1 α or 10 µM MT or 
325 nM Phorbol 1- Myristate 13- Acetate (PMA) for 5 minutes or 2 minutes. After stimulation, 
the cells were fixed using 4% paraformaldehyde for 20 minutes and then permeabilized using ice 
cold methanol. The cells were then stained for phosphorylated ERK1/2 using anti-human pERK 
antibody (diluted 1:1000 in FACS buffer) for 30 minutes at RT.  After incubation, the cells were 
then stained with the anti mouse IgG- FITC labeled secondary antibody for 30 minutes at RT. 
The cells were then washed and resuspended in FACS buffer and analyzed for pERK staining 
using Fortessa Analyzer. 
 
2.11 Measurement of CXCR4 expression 
	  
Jurkat T cells (5 x 105  / condition) were incubated with or without 10 µM MT or 12.5 
nM SDF 1 α for 20 minutes at 37 °C with 5% CO2. The cells were then washed with FACS 
buffer and incubated with 1 µg anti human CXCR4 antibody (Bio legend Cat# 306502) for 45 
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minutes on ice in the dark. The cells were washed and stained with 10 µg anti mouse IgG- FITC 
(Immunopure Cat#31565) diluted in 50 µl FACS buffer. After incubation the cells were washed 
and suspended in 200 µl FACS Buffer in 12x75mm tubes and fixed with 4% paraformaldehyde. 
CXCR4 expression was detected using the BD Biosciences LSRFortessa X-20 Cell Analyzer, 
and analyzed suing FlowJo Software. 
 
2.12 MT biotinylation 
	  
A.  Calculations 
• Calculate millimoles of biotin reagent (EZ-Link NHS-LC-biotin, Thermo Scientific 
Cat 21336) to add to the reaction for 20-fold molar excess: 
0.5 ml MT  x  1 mg MT   x  1 mmol MT  x  20 mmol Biotin = 0.0028571 mmol biotin 
                   0.5 ml MT    7000 mg MT         1 mmol MT 
• Calculate microliters of 10 mM biotin reagent solution to add to the reaction: 
0.0028571 mmol Biotin x 1,000,000 µl x       L      = 285.7 µl biotin reagent 
                           L                  10 mmol 
B. Labeling Reaction 
The starting concentration of MT was 2 mg/ml in PBS. Immediately before use 10 mM 
solution of the biotin reagent in an organic solvent (DMSO) was prepared by dissolving 2.3 mg 
NHS-LC-biotin in 500 µl DMSO. 285.71 µl of 10 mM biotin was added to the protein solution. 
The reaction was incubated on ice for 2 hours or RT for 30 minutes. The non-reacted and 
hydrolyzed biotin reagent was removed by using Zebra Spin desalting Columns (Thermo 
Scientific Cat 89891). The desalting column was washed with 2.5 ml wash buffer (PBS) and 
centrifuge for 2 minutes at 1000xg. The flow through was discarded and the wash was repeated 
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twice. Then the sample was applied on top of the resin. As soon as the sample has entered the 
resin, a stacker volume of 100 µl PBS was added. After centrifugation for 2 minutes at 1000xg 
flow-through, which contains sample was collected.  
C. Biotinylation calculation:  
The HABA/Avidin premix (Pierce Biotin Quantitation Kit Thermo Scientific Cat # 28005) 
was equilibrated to RT and diluted with ultrapure water. The absorbance of HABA/Avidin 
premix solution was measured at 500 nm and recorded as A500 HABA/avidin. 20 µL of 
biotinylated sample or Biotinylated HRP (positive control) was added to the well containing the 
HABA/avidin reaction mixture. The absorbance of the solution was recorded at 500 nm as noted 
as A500 HABA/avidin/biotin sample once the value remains constant for at least 15 seconds. 
Then Calculation of Moles of Biotin per Mole of Protein was done as follows 
Calculations: 
These calculations are based on the Beer Lambert Law (Beer’s Law) : Aλ=ελbC, where:  
A is the absorbance of the sample at a particular wavelength (λ). The wavelength for the HABA 
assay is 500nm. There are no units for absorbance. 
ε  is the absorptivity or extinction coefficient at the wavelength (λ). For HABA/avidin samples at 
500nm, pH 7.0 extinction coefficients is equal to 34,000 M-1cm-1. 
b is the cell path length expressed in centimeters (cm). A 10mm square cuvette has a path length 
of 1.0cm. Using the recommended microplate format volumes, the path length is typically 0.5cm. 
C is the concentration of the sample expressed in molarity (=mol/l = mmol/ml). 
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Chapter 3: Metallothionein in the extracellular environment 
	  
3.1 Introduction 
	  
	   Metallothionein was traditionally considered to be an intracellular protein as it lacks the 
signal peptide sequence or other protein trafficking signals that are found proteins that are 
targeted towards the extracellular environment. Regardless, there is evidence documenting MT’s 
presence in extracellular spaces such as serum, milk, urine, bronchoalveolar and prostatic fluids, 
live sinusoids, and pancreatic ducts [7]. MT has also been reported at the sites of inflammation 
and tissue wounding [64-66]. Some studies suggested that the presence of MT in the 
extracellular environment such as blood might be as a consequence of damaged cells leading to 
leakage through cell membrane or necrosis [67]. However, MT was secreted by adipocytes in 
cell culture as well as in supernatants from cell cultures without significant cellular damage 
suggesting that MT is selectively secreted or released [209]. Hence, this chapter will focus on 
MT in the extracellular environment and the possible mode of secretion.  
 
Protein secretion pathway  
Soluble secretory proteins that are part of the classical protein secretion pathways contain 
N-terminal signal peptides that direct their insertion into the endoplasmic reticulum (ER). These 
proteins exit the ER via COPII-coated vesicles and then transport into the Golgi apparatus from 
where they are released into the extracellular compartments by fusion of the Golgi-derived 
secretory vesicles with the plasma membrane. Soluble proteins leave the cells by exocytic 
process whereas membrane bound protein become integrated to the outer membrane. 
Additionally, some specialized secretory cells have regulated pathways, which enables them to 
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store the soluble proteins in secretory vesicles that can be released in response to specific signals. 
Some proteins such as interleukin 1β (IL-1β) and galectin-1 were shown to be secreted outside 
the cells without the ER/Golgi system [210, 211]. This list of proteins that are secreted via non-
classical pathway has expanded in recent years and includes proteins such as fibroblast growth 
factors 1 and 2 (FGF-1, FGF-2), heat shock proteins, etc. [212] . 
 
Unconventional protein secretion 
Unconventional protein secretion (UPS) is the transport of proteins to the plasma membrane 
or extracellular environment without the ER/Golgi dependent protein secretion. Most of the 
proteins that undergo UPS have been shown to be involved in cellular stress, inflammatory 
response or tumor-induced angiogenesis [213, 214]. There are two main categories of proteins 
that are secreted via UPS. The first category includes proteins that are active in the extracellular 
environment but lack the signal peptide or a transmembrane domain called “leaderless” proteins. 
Leaderless proteins are secreted via three mechanisms: Type I, or pore-mediated translocation, 
Type II or ABC transporter based secretion, and Type III or autophagosome/exosome based 
secretion. The other category incudes proteins with the signal peptide and/or transmembrane 
domain that enter the ER but bypass the golgi apparatus. These proteins are secreted via type IV 
or Golgi-bypass pathway [215].  
The Type I pathway involves the formation of pores in the plasma membrane to allow 
cytoplasmic protein to translocate across the plasma membrane in a regulated manner. This 
process is either self-sustained as in the case of Fibroblast Growth Factor 2 (FGF2) and HIV 
Transactivator of Transcription (TAT) or driven by inflammation leading to quick release of 
proteins such as cytokines IL-1 β [216-218]. Type III pathway has been shown to be stress-
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mediated and involved membrane bound organelles such as exosomes and autophagosomes and 
is used by proteins such as Heat shock protein 70 (Hsp70) [219]. 
As mentioned previously, metallothionein was considered to be an intracellular protein as it 
lacks the signal peptide sequence found in secreted proteins and thus most of the research done 
on metallothionein was focused on its intracellular functions. However, there is evidence 
documenting the presence of MT in the extracellular environment. Hence, we investigated the 
possible mechanism for MT secretion in the extracellular environment.  
 
3.2 MT secretion by Jurkat T cells 
	  
	   Jurkat T cells were treated with different non-toxic concentrations of cadmium chloride 
(CdCl2) overnight in cell culture media. The following day, cell culture supernatant was tested 
for presence of MT using competition ELISA. Briefly, the supernatant was incubated with the 
monoclonal antibody, UC1MT and added to wells of the plate coated with MT. The MT present 
in supernatant competed with binding of UC1MT to the MT coated on the plate. The 
concentration of MT present in supernatant was determined by using the standard curve of 
competition with known concentrations of MT. As seen in Figure 3.2, MT was detected in the 
supernatant of cells treated with 20 µM, 10 µM and 5 µM CdCl2.  
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A. 
 
B. 
 
Figure 3.2 
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Figure 3.2. MT secretion by Jurkat T cells following treatment with CdCl2: Plate was coated 
with 500 ng/ml of MT and incubated overnight at 4 °C. Wells were washed with PBST and 
blocked with 2% BSA in PBS for 1.5 hours at RT. Wells were washed, coated with dilutions of 
MT standards and UC1MT along with the cell culture supernatants and UC1MT, incubated for 2 
hours at RT. Plate was washed and incubated with 1 µg/ml anti-mouse IgG -biotin for 1 hour at 
RT. Plate was washed and incubated with streptavidin-HRP for 20 minutes at RT. After a final 
wash, substrate was added and incubated for 20 minutes at RT before addition of stop solution 
(2N H2SO4) and OD450 measured in Spectramax plate reader. A standard curve was generated for 
the competition ELISA with known MT concentrations (A), which was then used to determine 
the concentration of MT in cell culture supernatant after CdCl2 treatment (B). 
Error bars represent standard deviation 
Data representative of 3 separate experiments 
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3.3 MT release in the extracellular environment 
 
We have previously shown that when cells are treated GolgiStop and GolgiPlug, which are 
protein transport inhibitors that blocks the release of cargo from the Golgi, MT is still present in 
the extracellular environment (unpublished data). This suggests that MT release is not dependent 
on the classical ER-Golgi secretion pathway and that MT might be secreted via the 
unconventional secretion pathway (UPS). One of the most well known UPS pathway for stress 
related protein such as Hsp70 is the Type III pathway, which is mediated via exosomes. Hence, 
we investigated whether MT’s secretion involved Type III secretion pathway.  
Jurkat T cells were cultured overnight with or without 20 µM CdCl2 in cell culture media. 
The following day, exosomes were isolated from the cell culture media using total exosome 
isolation kit. The exosomes are isolated by the reagent, which ties up the water molecules 
causing the less soluble components such as exosomes to fall out of solution. The isolated 
exosomes were either lysed using RIPA buffer or directly used for SDS-PAGE analysis.  The 
samples along with a positive control MT (0.5 µg or 1 µg per lane) were run on a 15% SDS 
PAGE gel to electrophoretically separate the proteins present in each sample. After separation, 
the proteins were visualized by silver stain. As seen in Figure 3.3A, there were several proteins 
detected under different conditions along with the positive control MT which runs at 10-14 kDa 
due to protein dimerization. To selectively visualize our proteins of interest, western blot 
experiments were done. After electrophorectically separating the proteins on an SDS PAGE gel 
as described above, the proteins were transferred onto a PVDF membrane and probed for either 
Hsp70 (positive control) using anti Hsp70 antibody (Figure 3.3B) or MT using UC1MT, which is 
a monoclonal antibody against MT (Figure 3.3C). As expected, there was Hsp70 detected in 
	   46	  
exosomes after treatment with CdCl2 but there was no MT detected. This suggests that MT is not 
secreted by the Type III UPS pathway via exosomes.  
A. 
 
B. 
 
Figure 3.3 
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C. 
 
 
Figure 3.3. MT is not secreted via exosomes: Jurkat T cells were treated with or without 20 µM 
CdCl2 overnight at 37 °C with 5% CO2 and the exosomes were isolated from the cell culture 
media using exosome isolation kit. The exosomes were lysed with RIPA buffer and then the 
samples were run on a 15% SDS PAGE Gel. The proteins were visualized by Silver Stain  (A) or 
probed for Hsp70 via Western Blot using anti Hsp70 antibody (B) and MT with UC1MT (C). 1 
µg MT was used as a positive control for the Western Blot. 
Data representative of 3 separate experiments 
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3.4 MT binding to the surface of Jurkat T cells 
 
Previous studies have shown that MT can bind to the surface of lymphocytes [8]. Since 
there was MT secreted by Jurkat T cells after stimulation with CdCl2, we investigated whether 
MT bound to the surface of Jurkat T cells in culture. Cells were stimulated overnight with 20 µM 
CdCl2, and then the MT bound to the surface was detected by monoclonal antibody UC1MT 
tagged to Alexa Fluor 647 using the LSRFortessa X-20 Cell Analyzer. MT was found on the 
surface of Jurkat T cells after stimulation (Figure 3.4.1). Additionally, similar experiments were 
done with addition of exogenous MT. Jurkat T cells were incubated with a range of 
concentration of biotinylated MT for an hour at 37 °C with 5% CO2.  MT present of the surface 
of Jurkat T cells was detected by streptavidin conjugated with Alexa Fluor 647 using the 
LSRFortessa X-20 Cell Analyzer (Figure 3.4.2). Exogenously added MT was also detected on 
the surface of Jurkat T cells.  
A. 
 
 
Figure 3.4.1 
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B. 
 
Figure 3.4.1. MT secreted after CdCl2 stimulation binds to the surface of Jurkat T cells:  
Jurkat T cells were stimulated with 20 µM CdCl2 at 37 °C at 5% CO2 overnight in cell culture 
media. MT bound to the surface was detected by UC1MT (a monoclonal antibody against MT) 
tagged with Alexa Fluor 647 using the LSRFortessa X-20 Cell Analyzer illustrated by the dot 
plot (A) and histogram (B). MOPC21-Alexa Fluor 647 was used as an isotype control. 
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A. 
 
 
Figure 3.4.2  
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B. 
 
 
Figure 3.4.2. MT binds to the surface of Jurkat T cells: Jurkat T cells (5 x 105 / condition) 
were pre-incubated with or without different concentrations of MT-biotin for an hour at 37 °C 
at 5% CO2 in cell culture media. MT bound to the surface was detected by Streptavidin- Alexa 
Fluor 647 using LSRFortessa X-20 Cell Analyzer illustrated by the dot plot (A) and histogram 
(B). 
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3.5 Conclusions 
	  
MT is secreted into the extracellular environment by Jurkat T cells after treatment with 
cadmium chloride. Non-essential divalent metals like Cd lead to an increase in the intracellular 
concentration of Zn by displacing them from MT molecules. The displaced Zn can then bind to 
MRE sequences and lead to increased transcription of MT. This secretion method did not 
involve necrosis or cellular death as the treatment conditions were non- toxic for Jurkat T cells 
(data not shown). These results indicate that there is a selective pathway for MT release in the 
extracellular environment. Due to the absence of signal peptide sequence, we investigated 
whether MT secretion followed some of the known unconventional protein secretion pathways. 
Since MT is a stress response protein, we investigated if it is secreted via type III UPS which is 
used by other stress response proteins such as Hsp70. Intriguingly, our results indicate that the 
secretion of MT does not occur through the exosome mediated type III unconventional protein 
secretion pathway. As mentioned previously cytokines such as IL-1β, which need to be 
released quickly and in a large amount following cases of inflammation, have been shown to 
be translocated by heterologous pore formation in the plasma membrane [220]. There are 
additional pathways such as exovesicular membrane blebbing and partially folded “molten 
globule state” that have been suggested as other pathways of for non-conventional protein 
secretion [221, 222]. Most of these unconventional protein secretion pathways are new areas of 
research and not fully understood. Hence, the definitive understanding of MT release in the 
extracellular environment is challenging and requires further investigation. 
 The secreted MT can then bind to the surface of Jurkat T cells as shown by the 
presence of MT on the surface of Jurkat T cells after treatment with CdCl2. The binding of MT 
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on the surface of Jurkat T cells was further demonstrated by addition of exogenous MT. There 
was robust binding of MT on the surface of Jurkat T cells, which is consistent with other 
studies documenting the presence of MT on the surface of leukocytes harvested from 
congenitally autoimmune animals, and on cells cultured in the presence of mitogens [8].  
Under normal conditions, MT is an intracellular protein. However, MT is found in 
extracellular compartments under stressful conditions.  The released MT can act as a pro- 
inflammatory response and mediate events such as cellular chemotaxis. Additionally, since MT 
has been shown to play important role in wound healing, inflammation, and the immune 
response, extracellular pool of MT can act as a danger signal for the immune response in the 
context of different disease conditions. The role of MT in the extracellular environment is 
discussed in the following chapters. 
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Chapter 4:  Metallothionein’s role in chemotaxis 
 
4.1 Introduction 
 
Mammalian metallothioneins are about 60 to 68 amino acids in length. Despite its small 
molecular weight, MT is a cysteine- rich protein. The cysteine residues that are present in MT 
are arranged in cys-cys, cy-X-cys and cyx-X3-cys motifs, which are similar to those found in 
different chemokine families. The location of MT genes on human and mice chromosome is 
very close to chemokines CCL17 and CxCLII. Hence we investigated whether MT had any 
chemotactic properties. We have previously shown that MT can act as a chemoattractant for 
Jurkat T cells and this response can be blocked by the monoclonal antibody UC1MT. G Protein 
Coupled Receptor (GPCR) antagonists Cholera Toxin and Pertussis Toxin also block the MT 
chemotactic response and exposure of cells to MT leads to a rapid increase in F- actin content. 
These results suggested that the MT mediated chemotactic response might involve GPCR 
signaling cascade [13]. 
Chemokines are secreted in response to signals such as inflammation and they play an 
important role in recruitment of different cells types. Cells such as monocytes, neutrophils, and 
lymphocytes that express appropriate chemokine receptors respond to a chemokine gradient 
and participate in the biological response.  For this study, the focus will be on chemokines 
SDF-1, CCL2, and RANTES, which represent two of the most common classes of chemokines, 
as well as their corresponding receptors. 
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4.1.1 Stromal cell- Derived Factor-1  (SDF-1)/ CXCL12  
	  
 Stromal cell-derived factor 1 (SDF-1), also known as C-X-C motif chemokine 12 
(CXCL12) is a chemokine belonging to the CXC chemokine family, which is expressed in 
several tissues types including bone marrow, lungs, lymph nodes, heart, thymus and liver 
[223]. SDF-1 is highly conserved across species and has different isoforms based on the 
splicing variants. Out of the different isoforms, SDF-1α/CXCL12a and SDF-1β/CXCL12b are 
the two main isoforms that are ubiquitously expressed [224, 225]. There is a pro-SDF-1 form 
that contains signal peptide (21 amino acids at the N terminus) that gets cleaved to form the 
secreted SDF-1 [101]. SDF-1 consists of flexible N terminus connected by an extended “N-
loop”, a three-stranded β sheet followed by an α-helix. Conserved cysteine residues that form 
two disulfide bonds stabilize this structure [226]. SDF-1 binds to negatively charged 
glycosaminoglycans (GAGs) on the cell surface or in the extracellular matrix, which leads to 
leucocyte adhesion to the endothelium leading to cell migration. GAGs also prevent the 
proteolytic cleavage of SDF-1 and facilitate its oligomerization [227, 228].  
 
CXCR4 
	  
 CXCR4 is a seven transmembrane G- protein Coupled Receptor that is highly 
expressed in variety of cell types such as lymphocytes, endothelial, epithelial and 
hematopoietic stem cells, stromal fibroblasts and cancer cells [229]. CXCR4 differs from other 
GPCRs in the orientation of its α helices which is two helical turns longer allowing the 
formation of disulfide bond with N-terminal region, which is important for its interaction with 
SDF-1 [230]. Some of earliest research to understand chemokine-ligand interaction was done 
	   56	  
with IL-8 and its receptor, which highlighted an important role of chemokine’s N-terminus in 
receptor binding and activation [231]. Subsequent research on receptor-ligand interaction has 
revealed that there is a “two –site model” of receptor activation. This model states that N 
terminus domain of a receptor interacts with ligand’s core domain (chemokine recognition site 
1) and the N terminus of ligand interacts with the receptor ligand binding pocket (chemokine 
recognition site 2) [232]. Similarly SDF-1’s residues 12-17 bind to receptor CXCR4 that leads 
to a conformation change of the receptor, which then interacts with the 1-8 N-terminal residues 
of the chemokine and leads to receptor activation [226]. 
 The expression of CXCR4 is regulated by transcription factors Nuclear Respiratory 
Factor 1 (NRF-1) and Ying Yang 1 (YY1). NRF-1 promotes receptor transcription whereas 
YY1 is the negative regulator [233, 234]. Signaling molecules such as secondary messengers 
(calcium, cyclic AMP), cytokines (IL-2, IL-4, IL-7, IL-10, IL-15, TGF-β), and growth factors 
(FGF, VEGF) can also increase the transcription of CXCR4. On the contrary, cytokines such as 
TNF-α, INFγ and IL-1 β have been shown to down regulate the expression of CXCR4. CXCR4 
undergoes posttranslational modifications such as phosphorylation, glycosylation, 
ubiquitiation, and sulfation, which modulate its intracellular signaling components [228]. 
 
SDF-1 and CXCR4 axis 
	  
Hematopoiesis and immune cell trafficking 
 SDF-1 or CXCR4 deficiency is lethal in mice and this chemokine signaling axis has 
been shown to be essential for B cell development in the fetal liver and bone marrow (BM) 
[235]. SDF-1 is the most abundant chemokine in the BM, which is produced by a variety of 
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cell types including stromal and CXCL12-abundant reticular (CAR) cells, osteoblasts and 
nestin-expressing cells. Recent studies showed that the number of hematopoeitic stem cells 
(HSCs) was much lower in CAR-depleted mice [236]. Additionally, deletion of SDF-1 from 
CAR cells and osteoblasts caused a reduction in number of HSCs and B cell progenitors in the 
BM [237]. Another study highlighted the role of CXCR4 and SDF-1 axis in regulation of 
quiescence and self -renewal of primitive HCS [238]. Based on this evidence, it can be 
concluded that CXCR4 and SDF-1 axis is critical in the regulation of HSC quiescence, 
retention and differentiation. 
 SDF-1 and CXCR4 signaling also plays an important role in regulation of leukocyte 
trafficking in the thymus and lymph nodes. In the thymus, CXCR4 is required for the migration 
of DN1 cells and development of DN2 and later stages [239]. There is a reduction in number of 
B cells in splenic marginal zone and primary follicles and impaired T-independent antibody 
response as a result of CXCR4 inactivation in B cell lineage [240]. Additionally, SDF-1 along 
with CCL5 secreted by antigen presenting cells can act as costimulatory signals for activation 
and cytokine production by T cells [241]. 
 
SDF-1 & CXCR4 in disease 
 CXCR4 is expressed on almost all leucocytes and plays important roles in B and T 
lymphocyte trafficking as already described. Truncating mutation of CXCR4’s C-terminal 
domain of cytoplasmic tail led to continuous activation of the receptor resulting in 
abnormalities in different humoral and cellular immunity. These abnormalities were seen in 
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syndromes such as warts, hypogammaglobulinemia, bacterial infections, and mylokathexis 
(severe chronic neutropenia with hyperplasia of mature myeloid cells in bone marrow) [242].  
SDF-1 and CXCR4 axis has been implicated in several hematological malignancies and 
different types of tumors and cancers. CXCR4 is overexpressed in cases of chronic 
lymphocytic leukemia (CLL), acute myleiod leukemia (AML), multiple myeloma (MM) and 
lymphomas and this chemokine receptor axis is important in dissemination of these 
hematological neoplasms [185, 243]. AMD3100, which is a specific inhibitor of CXCR4, is 
currently being used in clinical trials as a treatment strategy for glioma, AML and 
neuroblastoma [243]. 
 The binding of SDF-1 to CXCR4 expressing cells in solid tumors such as breast, 
prostrate, colon, and lung cancer has been shown to confer metastatic properties [243]. In 
breast tumor tissues there was a significant correlation between HER2 and CXCR4 expression 
and the high expression of CXCR4 was associated with poor survival in patients with breast 
cancer [185, 244]. The blockade of CXCR4 with AMD3100 in MMTV-PyMT model of breast 
cancer was shown to reduce tumor burden by decreasing M2 tumor-associated macrophages 
after chemotherapy [245]. The use of AMD3100 also led to inhibition of tumor growth and 
metastasis in melanoma. Conversely, SDF-1 expression by stromal cells in primary melanoma 
microenvironment was shown to prevent the metastasis highlighting different roles of SDF-1 
[246, 247]. The administration of anti-CXCR4 antibody for the treatment of breast cancer cells 
in an intravenous tail-vein injection model and an orthotopic implantation model led to 
reduction of metastasis to lungs [186]. Additionally, overexpression of CXCR4 in pancreatic 
cancer cells and in murine melanoma cells resulted in significant increase in lung metastasis as 
well as liver metastasis [248, 249].  
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Some studies have shown that stimulation by SDF-1 results in increased proliferation 
and survival of CXCR4 expressing cancer cells [248, 250]. Additionally, upregulation of 
CXCR4 was seen under hypoxic conditions and was dependent on PI-3K signaling pathways, 
which also inhibits apoptosis allowing tumors to withstand hypoxic conditions [251].  These 
findings indicate that activation of CXCR4 can increase the metastatic properties, growth and 
survival of cancer cells.  
 
CXCR4-CCR5 and Human Immunodeficiency Virus 
 CXCR4 was identified as a co-receptor for Human Immunodeficiency Virus (HIV) to 
infect CD4+ T lymphocytes by Berger et al. [252]. Subsequently, CCR5 was also identified as 
another co-receptor. The attachment of HIV to CD4+ T lymphocytes leads to a conformational 
change in the virus’ subunit gp120, which exposes the hidden receptor-binding site. The gp120 
physically binds to co-receptors and leads to a second conformational change. This allows 
other HIV subunit gp41 to penetrate the cell membrane and form six helices bundle followed 
by fusion between the cell membrane and viral membrane leading to the infection [253]. 
 
4.1.2 Monocyte Chemoattractant Protein (MCP-1) / CCL2  
	  
 Monocyte chemoattractant protein (MCP-1), also known as CCL2 belongs to the C-C 
chemokine family and is a potent chemoattractant for monocytes. CCL2 is located on 
chromosome 17 and the mature protein is 13 kDa in size. Different cell types secrete CCL2 
constitutively or as a result of induction by oxidative stress, cytokines or growth factors. 
Mutational analysis has highlighted the critical role of regions Thr-10 to Tyr- 13 and residues 
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34-35 for biological function of the chemokine. Additionally, deletion of residues in the N 
terminus region results in loss of CCL2 activity [254]. The secondary structure of CCL2 
consists of four β sheets and two helical regions. CCL2 can also exist as a dimer, similar to 
other chemokines such as RANTES and MIP-1β [255].  
 CCL2 is produced by a variety of cell types such as endothelial cells, fibroblasts, 
epithelial, smooth muscle, mesangial, astrocytic, monocytic, and microglial cells. Monocyte/ 
macrophages were found to be the most potent source of CCL2 [256, 257]. Knockout studies 
done with CCL2 or its receptor result in viable mice, however there were abnormalities in 
monocyte recruitment and cytokine expression in these mutant animals [258]. CCL2 is one of 
the most studied chemokines in the C-C family as it has been shown to play important roles in 
immune response, diseases and several forms of cancer.  
 As mentioned previously, the C-C chemokines bind to their respective C-C receptors 
(CCRs). All human MCPs have been shown to bind at least two receptors and the CCRs can 
also bind several other ligands, which presents challenges for studying these chemokines and 
their receptors [259] . CCL2 preferentially binds to CCR2. However it can also bind to CCR4 
on cytotoxic T cells as well as Atypical Chemokine Receptors 1 and 2 (ACKR1 and ACKR2). 
The atypical receptors do not signal through G proteins and are regarded as decoy receptors 
[260]. There are two alternatively spliced forms of CCR2: CCR2A and CCR2B that differ in 
their C-terminal tails [261]. Mononuclear cells and vascular smooth muscle cells express 
CCR2A whereas monocytes and NK cells predominantly express the CCR2B isoform. CCR2B 
is the predominant isoform and accounts for 90% of all CCR2 expressed. Some studies have 
shown that these two isoforms can function via different signaling pathways and exert different 
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actions. For example: CCR2A mediated chemotaxis in response to CCL2 does not require 
calcium mobilization, which is seen in CCR2B mediated chemotaxis [262]. 
 
CCL2 in inflammatory disease 
 Several studies have linked CCL2 to cardiovascular diseases such as atherosclerosis. In 
the absence of CCL2 or CCR2, there is significant reduction in arterial lipid deposition as well 
as diminished number of macrophages that contribute to atherosclerosis [263]. Increased 
expression of CCL2 in the plasma is used as prognosis marker for early restenosis and a 
polymorphism in CCL2 promoter has been shown to be associated with increased risk of an 
individual to suffer from coronary heart disease [264, 265]. Induction of CCL2 by cytokines 
IL-4 and IL-13 in human bronchial epithelial cells was linked to asthma [266]. High CCL2 
levels were noted in patients with rheumatoid arthritis as well as neurological disorders such as 
ischemia related neuronal death [267, 268].  
 
CCL2 in cancer 
 CCL2-CCR2 axis has been shown to play a role in different stages of the metastatic 
cascade. CCL2 is expressed by cancer and stromal cells and can influence tumor cell 
proliferation at the primary site. It can also facilitate cell migration by interacting with CCR2 
expressed on tumor cells. CCL2 can also induce expression of metalloproteinases MMP2 and 
MMP9, which facilitate cancer metastasis. CCL2 in circulation can direct the dissemination of 
cancer cells and can also promote tumor growth at metastatic site by recruiting additional 
myeloid and endothelial cells [269]. 
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CCL2 and CCR2 have been implicated in different cases of cancer. For example: CCL2 
is expressed by endothelial cells in the prostate tumor microenvironment and plays an 
important role in their proliferation, migration and survival [270]. The inhibition of CCL2 had 
a very strong effect in decreasing the metastasis of prostate cancer into the bones [271]. CCL2 
is highly expressed by different breast cancer cell lines and was shown to promote different 
subsets of myeloid cells including Tumor Associated Macrophages (TAMs) [272]. The 
depletion of CCL2 lead to prolonged survival in a breast cancer mouse model [273]. This 
chemokine receptor axis has been shown to play an important role in pancreatic [274] as well 
as colorectal cancer [275].   
 
4.1.3 Regulated upon Activation Normal T-cell Expressed and Secreted (RANTES) / 
CCL5  
	  
 Regulated upon Activation Normal T-cell Expressed and Secreted (RANTES) is a C-C 
chemokine that is about 8 kDa in weight. RANTES was originally discovered as a T cell-
specific cytokine in the 1990s. Several studies have shown that RANTES can influence the 
migration of other cell types such as dendritic cells, eosinophils, NK cells, mast cells, etc. 
[276]. Appay et al. called RANTES a versatile and controversial chemokine due its role in 
several different biological processes besides chemotaxis [277].  RANTES can bind to 
receptors CCR1, CCR3 and CCR5 with highest affinity for CCR5 and CCR1. RANTES has 
been shown to participate in heterodimerization with other chemokines such as CXCL4 in vivo 
to enhance its biological function [276].  
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CCR5 
 CCR5 is expressed in immune cells such as macrophages, dendritic cells and memory T 
cells. It is also expressed in the endothelium, epithelium, vascular smooth muscle and 
fibroblasts as well as microglia, neurons, and astrocytes in the central nervous system [278]. 
CCR5 can bind to multiple ligands of which macrophage inflammatory protein one alpha 
(MIP1-α), macrophage inflammatory protein one beta (MIP1-β), monocyte chemotactic protein 
two (MCP-2) and RANTES are the natural ligands [279].  
 As mentioned previously, CCR5 has been shown to play an important role in 
replication and transmission of HIV. The tyrosine and acidic residues in the N terminal region 
of CCR5 are important in chemokine binding as well as during HIV infection. Farzan et al. 
demonstrated that the posttranslational modification of the tyrosine residue, which increases 
the negative charge, facilitates the binding of ligand and the virus [280]. Additionally, the 
serine residues of the N terminal region can undergo O-linked glycosylation modification that 
affects the binding of chemokines to CCR5 [281]. 
 
Biological functions of RANTES-CCR5  
 In response to a viral infection, CD8+ T cells release RANTES along with perforin and 
granzyme. Thus, RANTES has been shown to play an important role in the immune response 
to viral infection. Viruses such as human cytomegalovirus (HCMV) express a viral chemokine 
receptor analog US28 to sequester RANTES and evade the anti-viral response [282]. RANTES 
can also be induced by TNF-α and IFN-γ at later stages of infection [283]. The induction of 
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RANTES by viruses such as hantavirus, reovirus, adenovirus, coxsackie virus, rhinovirus, 
respiratory syncytial virus (RSV) and the well-known coronavirus and influenza virus has been 
well documented [276].   
 Interestingly, RANTES at high concentration (micromolar range) can activate T cells 
via non-GPCR mediated pathway. RANTES was shown to trigger a herbimycin A-sensitive 
protein tyrosine kinase (PTK) pathway leading to prolonged calcium influx, 
hyperphosphorylation and cell activation. This activation can lead to T cell proliferation or 
apoptosis and release of several pro-inflammatory cytokines such as IL-2, IL-5 etc. Some 
studies have shown that RANTES can aggregate at high concentrations and can lead to 
leukocyte activation [277].  
 RANTES-CCR5 axis has been implicated in several diseases. In asthma patients, 
RANTES can recruit eosinophils, monocytes and neutrophils leading to propagation of pro 
inflammatory response [284]. RANTES has been shown to play a very important role in 
several cases of atherosclerosis as described by Zernecke et al [285]. RANTES is 
overexpressed in different cases of cancers such as breast carcinoma, melanoma, and papillary 
thyroid carcinoma [276]. Additionally, RANTES has been shown to be a pro-angiogenic factor 
in studies with CCR5−/− mice that had reduced corneal neovascularization [286]. 
Results 
4.2 MT’s role as a chemoattractant  
	  
As mentioned previously, MT acts as a chemoattractant for Jurkat T cells. To 
investigate whether MT chemotactic response was specific for one cell type, chemotaxis 
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studies were done with MDA-MB-231 cells, an epithelial breast cancer cell line. SDF-1 α has 
been shown to be a potent chemoattractant for these cells [287] and was thus used as a positive 
control. MDA-MB-231 cells were added to the upper wells of a Boyden chamber and 
chemoattractants MT, SDF-1 α and cell culture media (negative control) were added to the 
wells of the lower chamber.  The cells and chemoattractants were separated by a polycarbonate 
membrane with 8 µm pore size and the cells that responded to the chemoattractant gradient 
crawled through the pores and stuck to the lower side, which were then stained and 
enumerated. MDA-MB-231 is an adherent cell line. Hence, to facilitate better movement of 
these cells the polycarbonate membrane was coated with fibronectin overnight before 
assembling the Boyden chamber. MT and SDF-1 α caused significant chemotaxis of MDA-
MB-231 cells, whereas the media control did not (Figure 4.2 A). Additionally, the chemotactic 
response of primary murine splenocytes towards MT was investigated using polycarbonate 
membrane with 3 µm pore size in the Boyden chamber assay. Spleen was harvested from a 
C57BL/6 mice and a single cell suspension was made following red blood cell lysis. The 
splenocytes consist of a variety of cell populations such as T and B-lymphocytes, macrophages 
and dendritic cells. Similar to MDA-MB-231 cells, there was significant chemotaxis of 
splenocytes towards MT (Figure 4.2 B). These results show that the chemotactic effect of MT 
is not specific for one cell type.  
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B. 
 
Figure 4.2 
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Figure 4.2. MT acts a chemoattractant for MDA-MB-231 cells and primary murine 
splenocytes: A) MDA-MB-231 cells at 2x106 cells/ml were exposed to MT (10 µM), SDF-1 α 
(12.5 nM) and cell culture media for 7 hours at 37 °C with 5% CO2. Cells that passed through 
the 8 µm pore membrane were stained and enumerated using a microscope.  
B) Primary murine splenocytes at 2x106 cells/ml were exposed to MT (10 µM), SDF-1 α (12.5 
nM) and cell culture media for 3 hours at 37 °C with 5% CO2. Cells that passed through the 3 
µm pore membrane were stained and enumerated using a microscope. 
Error bars represent standard deviation 
One way ANOVA analysis (*=p <0.05, ***=p <0.0001) 
Data representative of 3 separate experiments. 
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4.3 MT’s influence on chemotactic response towards SDF-1 α 
	  
We have previously shown that MT can bind to the leukocyte plasma membrane after 
both in vitro and in vivo exposures [8]. We have also established that MT can act as a 
chemoattractant for leukocyte cell lines as well as primary cells.  Chemokines and receptors are 
often promiscuous in their selectivity meaning one receptor can bind to multiple chemokines 
and vice versa. Hence we investigated whether MT might initiate chemotaxis via interaction 
with receptors for other chemokines. To test this hypothesis, Jurkat T cells were pre-incubated 
with MT in cell culture media for an hour. The cells were then washed and added to the upper 
wells of a Boyden chamber. Another population of cells without pre-incubation with MT was 
also included for comparison studies. The chemoattractants MT, SDF-1 α each diluted in cell 
culture media and media alone as negative control were added to the wells of the lower 
chamber. The cells and chemoattractants were separated by a polycarbonate membrane with 5 
µm pore size and the cells that responded to the chemoattractant gradient crawled through the 
pores and stuck to the lower side, which were then stained and enumerated. The population of 
cells that were pre-incubated with MT showed significant reduction in chemotactic response 
towards SDF-1 α (Figure 4.3.1 A). The Boyden chamber assay only establishes one steep 
chemotactic gradient. Hence additional chemotaxis studies were done using ECIS/Taxis assay, 
which establishes a gradient of chemoattractant after diffusion through an agarose matrix. 
Jurkat T cells pre-incubated with MT and another population of cells without pre-incubation 
were added to wells cut on the agarose overlay in the ECIS/Taxis chamber wells. A target 
electrode separates the two opposing wells of chemoattractant and cells. The cells that respond 
to the chemoattractant cross the target electrode causing a change in resistance, which is 
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recorded over time. Similar to the Boyden chamber assay, the population of cells that were pre-
incubation with MT showed reduction in chemotactic response towards SDF-1 α (Figure 4.3.1 
B).    
After establishing the inhibitory effect of MT on SDF-1 α- mediated chemotaxis, we 
investigated whether SDF-1 α can interfere with the chemotactic response of MT. To test this 
hypothesis, Jurkat T cells were pre-incubated with SDF-1 α in cell culture media for an hour. 
The cells were then washed and added to the upper wells of a Boyden chamber in parallel with 
population of cells not pre-incubated with MT. The chemoattractants MT, SDF-1 α and cell 
culture media (negative control) were added to the wells of the lower chamber. Cells that were 
pre-incubated with SDF-1 α showed significant inhibition in chemotactic response towards MT 
(Figure 4.3.2 A). Additional experiments were done with the ECIS/Taxis assay and the results 
were consistent with the Boyden chamber assay (Figure 4.3.2 B). These results indicate a 
possible interaction of MT with SDF- 1 α’ s receptor CXCR4 or the influence of MT in 
signaling pathways leading to SDF- 1 α mediated chemotactic response. 
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Figure 1: Jurkats at 2 X 106 cells/ml with and without preincubation with 
10µM MT for an hour were allowed to migrate in response to 100ng/ml SDF 
1-α for 3 hours at 37 °C.  One tailed t test with 
         ****p < 0.05 .
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Figure 4.3.1. Pre-incubation with MT causes significant inhibition of chemotactic 
response to SDF-1 α: A. Jurkat T cells at 2x106 cells/ml were pre-incubated with MT (10 µM) 
for an hour at 37 °C with 5% CO2. The cells were then washed and added to wells of the 
Boyden chamber. SDF-1 α (12.5 nM) and cell culture media were used as chemoattractants 
The Boyden chamber was incubated for 3 hours at 37 °C with 5% CO2. Cells that passed 
through the 5 µm pore membrane were stained and enumerated using a microscope.  
B.  Jurkat T cells at 2x106 cell/ml with or without MT pre-incubation were exposed to a 
gradient formed from a well containing either SDF-1 α (12.5 nM) or cell culture media in an 
ECIS/Taxis chamber. The change of resistance at 4000 Hz was monitored over a 45 hour 
period.  
Error bars represent standard deviation 
Unpaired t test (****=p <0.0001) 
Data representative of 3 separate experiments. 
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Figure 4.3.2. Pre-incubation with SDF- 1 α causes significant inhibition of chemotactic 
response to MT: A. Jurkat T cells at 2x106 cells/ml were pre-incubated with SDF-1 α (12.5 
nM) for an hour at 37 °C with 5% CO2. The cells were then washed and added to wells of the 
Boyden chamber assay.  MT (10 µM) and cell culture media were used as chemoattactants. The 
Boyden chamber was incubated for 3 hours at 37 °C with 5% CO2. Cells that passed through 
the 5 µm pore membrane were stained and enumerated using a microscope.  
B.  Jurkat T cells at 2x106 cells/ml with or without SDF-1 α (12.5 nM) pre-incubation were 
exposed to a gradient formed from a well containing either MT (10 µM) or cell culture media 
in an ECIS/Taxis chamber. The change of resistance at 4000Hz was monitored over a 50 hour 
period.  
Error bars represent standard deviation 
Unpaired t test  (***: p = 0.0004) 
Data representative of 3 separate experiments. 
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4.4. Specificity of MT mediated chemotactic response 
	  
 To investigate whether there was any cross reactivity between MT and chemokine 
SDF-1 α, studies were done to investigate the specificity of UC1MT, monoclonal antibody of 
MT. Experiments were done using ELISA as well as Boyden chamber assay to test the cross 
reactivity of the antibody against SDF-1 α. As seen in Figure 4.4.1, recombinant SDF-1 α 
bound to anti- SDF-1 α antibody (positive control) but not to UC1MT, which was coated on 
the plate. Similar experiment was done to test the cross reactivity of MT with anti SDF-1 α 
antibody and as seen in Figure 4.4.2, there was no reactivity between MT and anti SDF-1 α 
antibody. Additionally, Boyden chamber experiment was done to test the effect of UC1MT on 
the chemotactic response of Jurkat T cells towards MT and SDF-1 α. MT or SDF-1 α were pre-
incubated with UC1MT and then added to the chemoattractant wells of the Boyden chamber. 
MT or SDF-1 α without pre-incubation were used as positive controls. Jurkat T cells were 
added to the upper wells of the Boyden chamber and the chemotactic response was assessed 
after 3 hours. As seen in Figure 4.4.3, UC1MT was able to block the chemotactic response of 
Jurkat T cells towards MT but not SDF-1 α. 
 
 
 
 
 
 
	   75	  
 
 
Figure 4.4.1. UC1MT doesn’t bind to SDF-1 α: Plate was coated with 4 µg/ml of anti-SDF-1 
α or UC1MT and incubated overnight at 4 °C. Wells were washed with PBST and blocked 
with 2% BSA in PBS for one hour at RT. Wells were washed, coated with dilutions of SDF-1 α 
and incubated for 2 hours at RT. Plate was washed and incubated with 1 µg/ml anti-SDF-1 α -
biotin for 2 hours at RT. Plate was washed and incubated with streptavidin-HRP for 20 minutes 
at RT. After a final wash, substrate was added and incubated for 20 minutes at RT before 
addition of stop solution (2N H2SO4) and OD450 measured in Spectramax plate reader. 
Error bars represent standard deviation 
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Figure 4.4.2. MT is not bound by anti- SDF-1 α antibody: Plate was coated with 4 µg/ml of 
anti-SDF-1 α and incubated overnight at 4 °C. Wells were washed with PBST and blocked 
with 2% BSA in PBS for one hour at RT. Wells were washed, coated with dilutions of SDF-1 α 
& MT and incubated for 2 hours at RT. Plate was washed and incubated with 1 µg/ml anti-
SDF-1 α -biotin for 2 hours at RT. Plate was washed and incubated with streptavidin-HRP for 
20 minutes at RT. After a final wash, substrate was added and incubated for 20 minutes at RT 
before addition of stop solution (2N H2SO4) and OD450 measured in Spectramax plate reader. 
Error bars represent standard deviation 
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Figure 4.4.3. UC1MT does not block the chemotactic response of Jurkat T cells towards 
SDF-1 α: MT (10 µM) and SDF-1 α (12.5 nM) were pre-incubated with UC1MT (50 µg/ml) 
for an hour at 37 °C with 5 % CO2 and then used as chemoattractants. MT (10 µM) and SDF-1 
α (12.5 nM) and media alone were also used as additional chemoattractants by loading onto the 
bottom wells of Boyden chamber. Jurkat T cells at 2x 106 cells/ml were added to the top wells 
of the Boyden chamber and incubated at 37 °C with 5% CO2 for 3 hours. Cells that passed 
through the 5 µm pore membrane were stained and enumerated using a microscope. 
Error bars represent standard deviation 
Unpaired t-test, **: p= 0.005 
Data representative of 3 separate experiments. 
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4.5 MT as a promiscuous chemokine 
	  
Studies done in a DSS- induced colitis model in mice showed that blockade of MT at 
the sites of inflammation led to a decreased infiltration of macrophages [134]. These results 
hinted towards a possible role of MT in the chemotactic response of macrophages. To test this 
hypothesis, RAW 264.7, which is a macrophage cell line was used for chemotaxis studies. 
CCL2, which is a potent chemoattractant for macrophages, was used as a positive control for 
the following experiments. Boyden chamber assay was used to investigate the chemotactic 
response of RAW 264.7 cells towards MT and the results indicated that MT caused significant 
chemotaxis. Additional experiments were done where RAW 264.7 cells were pre-incubated 
with MT for an hour and the chemotactic response towards MT as well as CCL2 was 
measured. The pre-incubation with MT led to a significant reduction in chemotactic response 
of RAW 264.7 cells towards MT as well as CCL2 (Figure 4.5 A). These results were similar to 
those described in previous section with Jurkat T cells and SDF-1 α response. 
We also investigated the effect of MT on chemotactic response of monocytic cell line 
U937. There was a significant chemotactic response of U937 cells towards MT as well as 
RANTES, which was used as a positive control. Additionally, when U937 cells were pre-
incubated with MT, there was a significant inhibition in chemotactic response towards 
RANTES as well as MT (Figure 4.5 B). These results indicate that the MT mediated 
chemotactic response is not specific for one chemokine-receptor axis.  
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Figure 4.5. MT can influence the chemotactic response of RAW 264.7 cells and U937 
cells: A. RAW 264.7 cells at 2x106 cells/ml were pre-incubated with or without MT (10 µM) 
for an hour at 37 °C with 5% CO2. The cells were then washed and added to wells of the 
Boyden chamber assay.  MT (10 µM), CCL2 (7.5 nM) and cell culture media were used as 
chemoattractants. The Boyden chamber was incubated for 3 hours at 37 °C with 5% CO2. Cells 
that passed through the 5 µm pore membrane were stained and enumerated using a microscope.  
B. U937 cells at 2x106 cells/ml were pre-incubated with or without MT (10 µM) for an hour at 
37 °C with 5% CO2. The cells were then washed and added to wells of the Boyden chamber 
assay.  MT (10 µM), RANTES (25 nM) and cell culture media were used as chemoattractants. 
The Boyden chamber was incubated for 3 hours at 37 °C with 5% CO2. Cells that passed 
through the 8 µm pore membrane were stained and enumerated using a microscope. 
Error bars represent standard deviation 
Unpaired t test  (**: p = 0.001) 
Data representative of 3 separate experiments. 
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4.6 Conclusions 
	  
	   Here we have shown that metallothionein can act as a chemoattractant for different cell 
types: primary murine splenocytes, a macrophage and monocytic cell line. Cells such as 
leukocytes, monocytes, macrophages, etc. respond to chemotactic signals produced by 
infectious organisms or cells at the site of inflammation to mount an immune response. As 
mentioned previously, MT is secreted in response to acute phase cytokines that are a part of the 
inflammatory response. The chemotactic property of MT released at the sites of inflammation 
may help recruit different cell types that are involved in the inflammatory response.  
 Chemokine SDF-1 α and its receptor CXCR4 have been shown to play an important 
role in breast cancer cell migration and metastasis. The inhibition of CXCR4/SDF-1 α in 
cancer xenograft models resulted in reduced metastasis. Additionally, SDF-1 α has been 
implicated in cell migratory properties, cell survival, homing and resistance to treatment in 
different cases of breast cancer [287]. MT is proposed as a prognostic biomarker of breast 
cancer as it was found to be overexpressed in breast cancer patients correlating with chemo 
resistance [288]. We have shown that MT can act as a chemoattractant for MDA-MB-231 
cells. Hence, the overexpression of MT in breast cancer patients may facilitate the metastasis 
of breast cancer cells. Further investigation focusing on manipulations of MT in cases in breast 
cancer may provide unique opportunities for therapeutic intervention.	  
 We have shown that MT pre-incubation can lead to decreased chemotactic response of 
Jurkat T cells towards SDF-1 α. Additionally, pre-incubation with MT also caused significant 
reduction in chemotactic response to SDF-1 α. This effect was specific for MT and not a result 
of cross reactivity between UC1MT and MT or SDF-1 α. These results suggest a possible 
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interaction of MT with SDF-1 α’s cognate receptor CXCR4. The sequence alignment of MT 
with chemokine SDF-1 α highlights sequence similarity and several conserved amino acid 
sequences between MT and SDF-1 α (Figure 4.6). This similarity might contribute to 
interaction of MT with CXCR4, which be discussed in detail in the following chapter. 
 
Figure 4.6: Clustal Omega alignment of MT-1 with chemokine SDF-1: the sequence 
alignment of MT with SDF-1 shows fully conserved ( | ) strongly similar (:)  and weakly 
similar ( .) amino acid residues. 
 Our results also indicate that MT can influence the chemotactic response of CCL2 and 
RANTES, which belong to a different class of chemokine family (C-C) than SDF-1 α (C-X-C). 
As mentioned previously, MT is a cysteine rich protein and contains 20 cysteine residues. 
These residues are arranged in both C-C and C-X-C motifs. Thus different parts of the protein 
might be capable of mimicking different chemokines and possibly interacting with their 
corresponding receptors.  This interaction may lead to receptor desensitization and the 
subsequent inhibition in the chemotactic response. 
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Chapter 5: The role of G- Protein Coupled Receptor and related pathways 
in MT mediated chemotactic response 
	  
5.1 Introduction 
  
 Multiple lines of evidence have shown that MT can bind to the surface of cells. Refaeya 
et al. characterized the receptors for MT on human astrocytes by using fluoresceinated MT-1 
isoform probe on U373MG cell membranes but did not identify the protein [289]. Another 
study suggested megalin as a possible receptor of MT in rat retina [290]. While some 
membrane receptors of MT have been proposed [291, 292], this is still an area of active 
investigation. We have shown that MT can bind to the surface of lymphocytes and that MT can 
interfere with SDF-1α- CXCR4 mediated chemotactic response. Additionally, MT-mediated 
chemotactic response can be blocked by the GPCR antagonists Cholera toxin and Pertussis 
toxin. Hence, we hypothesized that CXCR4 is a receptor of MT on lymphocytes and MT 
mediate chemotactic response involves GPCR mediated signaling cascades.  
 The following section focuses on studies done with AMD3100; a specific antagonist of 
CXCR4, and signaling components of GPCR that might be involved in MT mediated 
chemotactic response along with MT peptides that contribute to the MT-receptor interaction. 
 
AMD3100 
 AMD3100 (AMD standing for AnorMeD) is a bicyclam molecule tethered by an 
aromatic bridge (Figure 5.2 A). This compound was originally called JM3100 and was 
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identified for its anti HIV activity. Vreese et al. showed that AMD3100 targeted the viral 
glycoprotein gp120, which was later shown to be via interaction with CXCR4 preventing the 
entry of HIV virus [293, 294].  
 AMD3100 is a specific antagonist of CXCR4 and was shown to inhibit CXCR4-
mediated calcium signaling and chemotaxis in a concentration dependent manner. 
Additionally, AMD3100 blocked the SDF-1 α endocytosis of the receptor. This effect was 
specific for CXCR4 as AMD3100 showed no interaction with receptors CXCR1 through 
CXCR3 as well as CCR1 through CCR9 [295]. AMD3100 binds to CXCR4 through 
interactions with three residues: Asp171 (AspIV:20), Asp262 (AspVI:23), and Glu288 (GluVII:06) 
that are present in ligand-binding pocket of the CXCR4 receptor [296]. 	  	  
 
5.2 Effect of AMD3100, CXCR4 antagonist, on MT mediated chemotactic response  
	  
Chemotaxis studies as described in Section 4.3 hinted towards a possible interaction of MT 
with the receptor CXCR4. To test this hypothesis, AMD3100, a specific antagonist of CXCR4, 
was used for chemotaxis studies. Jurkat T cells were treated with non-toxic concentrations of 
AMD3100 for 30 minutes at 37 °C and 5% CO2 in cell culture media and the chemotactic 
response to SDF-1 α was measured by Boyden chamber assay. As expected, AMD3100 
blocked the chemotactic response to SDF-1 α and the maximal effect was seen at 
concentrations 20 µM and 200 µM (Figure 5.2 B). Hence, those two concentrations were used 
for future experiments with the antagonist. To investigate whether MT mediated chemotactic 
response in Jurkat T cells involves CXCR4, Jurkat T cells were treated with AMD3100 (as 
described previously) and the chemotactic response to MT and SDF-1 α  (positive control) was 
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measured using Boyden chamber assay. The population of cells that were treated with the 
inhibitor had a significant reduction in chemotactic response towards MT suggesting that the 
MT mediated chemotactic response is via receptor CXCR4 (Figure 5.2 C).  
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Figure 5.2. AMD3100 blocks MT mediated chemotactic response: A. Structure of 
AMD3100 (Sigma). 
B. Dose response of AMD3100 treatment on Jurkat T cells chemotaxis towards SDF-1 α: 
Jurkat T cells at 2x106 cells/ml were pre-incubated with or without AMD3100 at 
concentrations ranging from 0 to 200 µM for 30 minutes at 37 °C and 5% CO2. The cells were 
then washed and added to wells of the Boyden chamber. SDF-1 α (12.5 nM) was used as 
chemoattractant and the Boyden chamber was incubated for 3 hours at 37 °C with 5% CO2. 
Cells that passed through the 5 µm pore membrane were stained and enumerated using a 
microscope 
Error bars represent standard deviation 
One-way Anova analysis, (****: p< 0.0001) 
C. Jurkat T cells at 2x106 cells/ml were pre-incubated with or without 20 µM AMD3100 for 30 
minutes at 37 °C with 5% CO2. The cells were then washed and added to wells of the Boyden 
chamber assay. MT (10 µM) and SDF-1 α (12.5 nM) were used a chemoattractants and the 
Boyden chamber was incubated for 3 hours at 37 °C with 5% CO2. Cells that passed through 
the 5 µm pore membrane were stained and enumerated using a microscope. 
Error bars represent standard deviation 
Unpaired t test  (**: p < 0.05) 
Data representative of 3 separate experiments. 
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5.3 Effect of AMD3100 on MT binding to the surface of Jurkat T cells 
	  
AMD3100 selectively and reversibly antagonizes the binding of SDF-1 α to CXCR4 [297]. 
To investigate whether MT binds to CXCR4 on Jurkat T cells, AMD3100 was used for surface 
binding studies. Jurkat T cells were treated with non-toxic concentrations of AMD3100 (20 
µM and 200 µM) for 30 minutes at 37 °C and 5% CO2 in cell culture media. A population of 
Jurkat T cells was left untreated (positive control). The cells were then washed and incubated 
with 2.5 µM MT-biotin for an hour 37 °C and 5% CO2. A suboptimal concentration of MT-
biotin was used for this experiment based on MT binding competition (as shown in Figure 
3.4B). MT bound to the surface was detected by streptavidin- Alexa Fluor 647. As expected, 
the MT-biotin was detected on the surface of Jurkat T cells without any AMD3100 treatment. 
The cells that were treated with AMD3100 at both concentrations showed reduced surface 
binding of MT-biotin (Figure 5.3). These results indicate that AMD3100 can interfere with 
MT’s interaction with CXCR4 on the surface of Jurkat T cells. 
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Figure 5.3. AMD3100 interferes with MT binding to the surface of Jurkat T cells: Jurkat T 
cells at 5 x 105 cells/ condition were treated with or without AMD3100 (20 µM and 200 µM) 
for 30 minutes 37 °C at 5% CO2. The cells were then washed and pre-incubated with MT-
biotin (2.5 µM) for an hour at 37 °C at 5% CO2 in cell culture media. Streptavidin- Alexa Fluor 
647 using the LSRFortessa X-20 Cell Analyzer detected MT bound to the surface illustrated by 
dot plots (A) and histogram (B). 
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5.4 MT peptides design and chemotaxis 
The study of ligand and receptor interaction, especially the transmembrane receptors 
such as GPCR have proven to be challenging because of conformationally flexible 
transmembrane proteins. Some of earliest research to understand this interaction was done with 
IL-8 and its receptor, which highlighted an important role of chemokine’s N-terminus in 
receptor binding and activation [231]. Subsequent research on receptor-ligand interaction has 
revealed that there is a “two –site model” of receptor activation. This model states that N 
terminus domain of a receptor interacts with ligand’s core domain (chemokine recognition site 
1) and the N terminus of ligand interacts with the receptor ligand binding pocket (chemokine 
recognition site 2) [232]. The β- strands and α helices act as a scaffold and can be swapped 
between chemokines whereas the N terminal residues are essential for binding affinity as well 
as receptor activation. For example the grafting of IL-8 N terminal, N-loop and 30s turn 
residues on CXCL10 enabled CXCL10 to bind and recognize CXCR1 and CXCR2 function 
(receptors for IL-8) [298]. Additionally, a N- terminal deletion mutant for RANTES resulted in 
a loss in specificity for its receptor and addition of a single methionine to the N- terminus was 
sufficient abolished its receptor activities [299, 300]. 
 
CXCR4- SDF 1 α interaction 
 Mutational analysis has shown that N terminus and the N –loop of SDF-1 α are 
essential for interaction with the receptor CXCR4 [226]. Kofuku et al. further demonstrated 
that SDF-1 β-sheet, 50 s loop, and N- loop interact with extracellular region of CXCR4 and the 
N-terminus of the chemokine interacts with transmembrane region of the receptor. 
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Additionally, the dynamic N terminal region of SDF-1 in the bound state plays a crucial role in 
“fly- casting” mechanism to search for the deeply buried binding pocket in the CXCR4 
transmembrane region [301]. 
 
MT peptides 
Rationale of peptide design: Previous studies done for MT epitope mapping has predicted 
that monoclonal antibody binding may be in the hydrophilic regions of 1-5 or 20-25 [302]. The 
MT peptides were designed based on the protein’s amino acid sequence to determine the 
region of MT that is most important for possible interaction with its receptor contributing to the 
chemotactic response. Each peptide consisted of 10 amino acid sequences (10-mer) and were 
designed based on the rabbit MT-1 sequence, as the full length MT protein used for this study 
is a rabbit MT-1, purchased from Enzo Life Sciences. Additionally, overlapping 10-mer 
sequence peptides and were also designed and used for this study as shown below. 
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Effect of MT peptides on chemotactic response towards SDF-1 α:  
The optimum concentration of MT peptides to be used in chemotaxis experiments was 
determined by competition ELISA (data not shown). The polystyrene plates were coated with 
full length MT protein (10 µg/ml) that competed with a range of MT concentrations pre-
incubated with UC1MT. The binding of UC1MT with MT coated on the plate after competing 
with free MT was used to generate a standard curve. Similarly, a range of concentration of 
each MT peptide was pre-incubated with UC1MT and then added to the plate coated with MT. 
With the use of standard curve, the optimum concentration of peptides competing with MT 
binding was determined and used for subsequent chemotaxis experiments. 
As mentioned previously, when Jurkat T cells are pre-incubated with MT, the 
chemotactic response towards SDF-1 α is significantly reduced. To investigate if there was a 
specific part of MT that was responsible for this inhibition, Jurkat T cells were pre- incubated 
with each of the MT peptides at 100 µg/ml for an hour at 37 °C with 5 % CO2. The cells were 
then washed and added to the chambers of Boyden chamber assay to test the chemotactic 
response to SDF-1 α. The pre-incubation with peptides MT1-10 and MT4-12 caused a significant 
inhibition in the chemotactic response towards SDF-1 α, comparable to that of the full-length 
protein (Figure 5.4). 
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Figure 5.4. The amino terminal end of MT appears to be involved in the inhibition of 
chemotactic response towards SDF-1 α: Jurkat T cells at 2x106 cells/ml were pre-incubated 
with MT peptides (100 µg/ml each) or intact MT (10 µM) for an hour at 37 °C with 5 % CO2. 
The cells were then washed and added to wells of the Boyden chamber assay. SDF-1 α (12.5 
nM) was used as a chemoattractant and the Boyden chamber was incubated for 3 hours at 37 
°C with 5% CO2. Cells that passed through the 5 µm pore membrane were stained and 
enumerated using a microscope. 
Error bars represent standard deviation 
One- way ANOVA (**: p < 0.05, ***: p= 0.0002, ****: p< 0.0001) 
Data representative of 3 separate experiments. 
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Mechanism of MT mediated chemotactic response 
Reactive Oxygen Species 
 Reactive oxygen species (ROS) are chemically reactive species containing oxygen such 
as peroxide, superoxide, hydroxyl radical and singlet oxygen. The main source of ROS in the 
cells is the mitochondrial complexes II and I. ROS is also produced by intracellular enzymes 
such as oxidases, lipoxygenases and cyclooxygenases that are present in the cytosol [303]. 
Under normal conditions, ROS play important roles in cell signaling and homeostasis and are 
regulated to maintain homeostasis by glutathione, thioredoxin, superoxide dismutase (SOD) 
and catalase systems [304]. The dysregulation of ROS homeostasis is detrimental to the cells 
and has been implicated in pathogenesis of cardiovascular diseases, diabetes, and different 
cases of cancer [305]. 
 
ROS mediated regulation of chemotaxis 
 The NADPH oxidase dependent ROS plays an important role in regulation of 
neutrophil chemotaxis. Neutrophils were shown to lose their directionality after forming 
multiple pseudopodia in ROS depleted environment [306]. An extracellular gradient of 
hydrogen peroxide generated by epithelial cells induced chemotaxis of neutrophils to the 
wound site. This chemotactic effect involved the sensing of locally generated hydrogen 
peroxide by Src kinase Lyn [307, 308]. Additionally, studies have shown that mice that lack 
p47phox or gp91phox subunit of NADPH oxidase (main source of endogenous ROS) exhibit 
higher infiltration of neutrophils than WT mice [309]. ROS has also been implicated in MCP-1 
mediated chemotaxis in smooth muscle cell migration. The depletion of ROS by NADPH 
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oxidase inhibitor completely blocked the chemotactic response of A7r5 (smooth muscle cell 
line) towards MCP-1 [310]. 
 In different cases of cancers and cell models, there is a correlation between CXCR4 and 
SDF-1 α up regulation and ROS. In B cells, depletion of ROS by N-acetylcysteine (NAC), 
which is an ROS scavenger, was shown to increase CXCR4 mediated activation of AKT [311]. 
There was reduced secretion of SDF-1 α from the bone marrow osteoblasts and endothelial 
cells following loss of ROS [312]. Chetram et al have shown that there is an increase in 
expression of CXCR4 after ROS treatment in prostate cancer cell line that also correlated with 
increased expression of p-AKT. Additionally ROS led to increased migration and invasion of 
prostrate cancer cell migration and CXCR4 antagonist AMD3100 blocked this response [313]. 
These results indicate that ROS plays a role in CXCR4 mediated chemotaxis response. As 
mentioned previously, MT has been shown to play important roles in regulation of ROS. 
Hence, we investigated the role of ROS in MT mediated chemotactic response. 
 
5.5 Role of ROS in MT Chemotaxis 
 
 CM-H2DCFDA, chloromethyl derivative of H2DCFDA, is a commonly used indicator 
of intracellular ROS. To test weather MT or SDF-1 α caused an increase in intracellular ROS, 
Jurkat T cells were stimulated with MT, SDF-1 α, or a positive control hydrogen peroxide 
(H2O2) for an hour and the change in intracellular ROS production was measured using CM-
H2DCFDA probe. The CM-H2DCFDA can diffuse passively into the cells and its acetate 
groups are cleaved by intracellular esterases. Subsequently, its thiol-reactive chloromethyl 
group reacts with intracellular glutathione and other thiols. This leads to production of a 
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fluorescent adduct after oxidation, which can be measured. After stimulation with MT or SDF-
1 α at the above-mentioned timepoint, there was no change in cellular ROS production. As 
expected H2O2 led to increased ROS production  (Figure 5.5A). Additionally, we investigated 
MT’s role as an ROS scavenger and if ROS affected MT mediated chemotaxis by comparing 
the response after pre-incubation with a biological antioxidant mercaptoethanol (2-ME). Jurkat 
T cells were pre-incubated with MT alone, 2-ME alone or a combination of both MT and 2- 
ME for an hour. The cells were then washed and the chemotactic response towards SDF-1 α 
was measured using the Boyden chamber assay after 3 hours. There was no effect on Jurkat T 
cells response towards SDF-1 α after pre-incubation with 2-ME or in combination with MT 
suggesting that the inhibitory chemotactic effect of MT is not solely because of its anti-oxidant 
properties (Figure 5.5B).  
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B. 
 
Figure 5.5. MT mediated chemotactic response does not involve its antioxidant activity: 
A. Jurkat T cells at 5 x 105 cells/ condition were stimulated with SDF-1 α (12.5 nM), MT (10 
µM) and H2O2 (50 µM) and the change in intracellular ROS was measured using CM-
H2DCFDA probe. The fluorescence readings were taken at: Excitation, 485 nm; Emission, 535 
nm 
B. Jurkat T cells at 2x106 cells/ml were pre-incubated with or without MT (10 µM) and 2-ME 
(10 µM or 100 µM) for an hour at 37 °C with 5% CO2. The cells were then washed and added 
to wells of the Boyden chamber assay. SDF-1 α (12.5 nM) was used a chemoattractant and the 
Boyden chamber was incubated for 3 hours at 37 °C with 5% CO2. Cells that passed through 
the 5 µm pore membrane were stained and enumerated using a microscope. 
Error bars represent standard deviation 
One way-ANOVA (**: p = 0.003, *: p= 0.01) 
Data representative of 3 separate experiments. 
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5.6 Role of GPCR mediated signaling molecules in MT mediated chemotaxis 
	  
Receptor Adaptation and Internalization 
Most of the known chemokines operate via transmembrane GPCR. The interaction of 
GPCR with a ligand leads to either induction of their own phosphorylation (homologous 
desensitization) or phosphorylation of other receptors (heterologous desensitization) [314]. 
This process of desensitization is mediated by uncoupling of heterotrimeric G proteins that 
prevents the receptor from transducing signal via its subunits Gα or Gβγ. In the absence of a 
ligand, the receptor can undergo resensitization by recycling [315]. The phosphorylation of C-
terminal domain of the receptor is mediated by G protein-coupled receptor kinases (GRKs). 
The phosphorylated receptors have decreased affinity for heteromeric G proteins and also 
increased affinity for β- arrestins. The binding of β- arrestin leads to receptor internalization, 
which can result in either recycling to the surface and resensitization or degradation and 
persistent desensitization [316]. Some studies have shown that the β- arrestins can also 
participate in the downstream signaling pathways, which will be discussed in more details in 
the following section.  
The process of homologous desensitization of CXCR4 is mediated by E4 ubiquitin ligase 
IAP4.  The ubiquitination of C terminal tail of the receptor tags it for lysosomal degradation 
via the endosomal-sorting complex required for transport (ESCRT) pathway. Ubiquitin binding 
domain (UBD) detects the ubiquitin tag on receptor and it gets transported to lysosome for 
degradation. This process reduces signaling in the presence of high concentration gradients and 
also stops chemotaxis when the cell reaches the source of chemoattractant [317].  
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Regulation of Heterotrimeric G proteins  
The binding of a chemoattractant to the receptor leads to a conformational change in the 
intracellular domain of GPCR, which results in the release of GDP from Gα subunit. Cytosolic 
GTP replaces the GDP and leads to the dissociation of three subunits as Gα-GTP and Gβγ 
dimer, each of which can regulate a series of downstream signaling as shown in Figure 5.6. 
The intrinsic GTPase activity of Gα can hydrolyze GTP to GDP and the inactive heterotrimeric 
complex can be reassociated [318, 319].  
The activation of the receptor occurs very rapidly (within milliseconds) with maximum 
dissociation of the heterotrimeric subunit occurring within 3 to 6 seconds after chemokine 
stimulation. The rate-limiting step in the activation cycle was shown to be the re-association of 
Gα-GDP and Gβγ and the receptor that takes about 15-30 seconds to a few minutes in 
mammalian cells [320]. The duration of downstream signaling is dependent upon the state of 
Gα and subunit in its GTP bound state. Hence, this process is tightly regulated by guanine 
exchange factors (GEFs), GTPase- activating proteins (GAPs), and guanine nucleotide 
dissociation inhibitor (GDIs).  GEFs can bind to Gα-GDP and facilitate the exchange of Gα-
GDP to active GTP-bound state. The intrinsic rate of GTP hydrolysis is enhanced by GAPs and 
upon hydrolysis of Gα, the heterodimer of Gα-GDP and Gβγ can reform restoring the GPCR/G 
protein complex. This process of recouping can be prevented by the presence of GDIs that can 
trap the Gα in a Gα.GDP/GDI complex [321]. Gβγ are regulated by phosducin and phosducin 
like protein (PhLP1) that mediate the association of Gβγ with Gα and Gβ with Gα respectively 
[322, 323]. Additionally, receptor of activated kinase 1 (RACK1) and WD40-repeat containing 
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protein 26 (WDR26) can mediate the interaction of Gβγ with its downstream effectors and can 
affect the chemotactic response [324, 325]. 
Chemotactic pathways activated by Heterotrimeric G protein 
The chemotactic signaling pathway includes a complex network of GPCR regulated 
interconnecting pathways that leads to amplification of the extracellular chemoattractant 
gradient as seen in Figure 5.6. There is preferential activation of monomeric G proteins at the 
leading edge of a migrating cell followed by changes in the cytoskeleton and actin 
polymerization. The coordinated cell movement is mediated by formation of pseudopodia at 
the leading edge by actin polymerization and actin-myosin filament inhibition of pseudopod 
formation in the rear of the cell [326]. 
The Gα subunit is divided into four subclasses Gα(s), Gα(i), and Gα(q/11), and Gα(12/13), 
which participate in specific signaling cascades. Gα(s) and Gα(i) regulate adenylate cyclases 
by stimulating and inhibiting the activity respectively. Gα (q/11) targets phospholipase C 
(PLC), which cleaves phosphatidylinositol 4,5-biphosphate into inositol triphosphate (IP3) and 
membrane bound diacylglycerol (DAG). Gα (12/13) signals via the Rho/ROCK pathway by 
activating Rho GEFs. Some studies have shown that individual GPCR interacts with only one 
specific Gα. However, there are evidences suggesting that multiple Gα can be activated by one 
GPCR with a marked preference for one [327]. 
 Deletion of single Gβ gene in Dictyostelium completely impaired the chemotactic 
response highlighting the importance of Gβγ subunit’s role in chemotaxis [328]. Gβγ interacts 
with Phosphoinositide 3-kinase (PI3K) in a Ras-dependent manner and leads to accumulation 
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of Phosphatidylinositol (3,4,5)-trisphosphate (PIP3) asymmetrically at the leading edge of cells 
providing a binding site for a subset of PH-domain containing proteins such as cytosolic 
regulator for the adenylyl cyclase (CRAC) and PKB/Akt (protein kinase B). The PKB/ Akt can 
regulate cell polarity and chemotaxis via myosin II assembly [329].  PI3K can also activate 
Rac small G proteins and regulate Wiskott-Aldrich syndrome protein (WASP) and the 
SCAR/WAVE complex, which stimulate the ARP2/3 complex [330]. Some studies have 
shown that Gβγ can directly activate PLCβ and its effector Protein Kinase C (PKC) [331]. 
 
Figure 5.6. The signaling cascade of GPCR ligand interaction: The binding of a 
chemoattractant to the receptor leads to a conformational change in the intracellular domain of 
GPCR, which results in the release of GDP from Gα subunit. Cytosolic GTP replaces the GDP 
and leads to the dissociation of three subunits as Gα-GTP and Gβγ dimer, each of which can 
regulate a series of downstream signaling. Adapted from [332, 333]. 
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The signaling cascade of GPCR- ligand interaction  
Chlolera toxin and pertussis toxin are known antagonists of GPCR. In case of cholera 
toxin, the α subunit causes ADP ribosylation of GTP, which results in constitutive activation of 
the G-protein subunits and exponentially raises cAMP levels in the eukaryotic cytosol leading 
to an impaired chemotactic response via GPCR [334].   Pertussis toxin blocks the release of 
GDP from the Gα subunit and prevents the activation of GPCR [335]. Previous studies in our 
lab have shown that the chemotactic effect of MT can be blocked by cholera and pertussis 
toxins [13], suggesting a possible role for GPCRs. Hence we investigated the implications of 
GPCR signaling pathways in MT mediated chemotactic response.  
 
5.6.1 Actin Related Protein 2/3 (Arp 2/3) 
	  
Arp 2/3 complex regulates the actin cytoskeleton by catalyzing the process of actin 
filament nucleation. Arp 2/3 binds to existing actin filaments and facilitates the binding of actin 
monomers by interacting with ATP, and activating proteins called nucleation-promoting 
factors (NPFs) [336]. As mentioned previously, one of the components of signal transduction 
through GPCR is the reorganization of F-actin leading to the formation of lamellipods towards 
the direction of cell movement [337]. We have previously shown that F-actin concentrations 
increase in cells upon exposure to MT. MT stimulated a 19% increase in total F-actin within 30 
seconds and a 79% increase by 2 minutes. [13]. To further investigate the role of Arp2/3 in MT 
mediated chemotactic response a small molecule inhibitor, CK-666 was used. CK-666 
stabilizes the inactive state of the Arp2/3 complex by blocking movement of the Arp2 and 
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Arp3 subunits into the activated filament-like conformation and thus prevents the nucleation of 
actin filament [338].  
 
Blockade of GPCR signaling cascade by CK-666 (Arp2/3 inhibitor)  
 Jurkat T cells were treated with a range of concentration of CK-666 to determine the 
optimum non-toxic concentration of the inhibitor. The treatment of Jurkat T cells with CK-666 
at 100 µM was non-toxic and caused significant reduction in the chemotactic response to SDF-
1 α (data not shown). This concentration of the inhibitor was used for subsequent studies. To 
investigate whether Arp 2/3 complex was involved in MT mediated chemotactic response, 
Jurkat T cells were treated with or without 100 µM CK-666 for an hour and the chemotactic 
response to MT was measured by Boyden chamber assay. The treatment of cells with CK- 666 
caused a significant inhibition of chemotaxis towards MT suggesting that Arp2/3 is involved in 
the MT mediated chemotactic response (Figure 5.6.1). 
A.  
 
Figure 5.6.1 
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C. 
 
Figure 5.6.1 
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Figure 5.6.1. Blockade of GPCR signaling cascade by CK-666 (Arp2/3 inhibitor) inhibits 
MT chemotaxis: A. Structure of CK-666, a small Molecule Inhibitor of Arp2/3 complex 
(Enzo life Sciences) 
B. Viability test for CK-666 using trypan blue exclusion assay 
C. Jurkat T cells at 2x106 cells/ml were pre-incubated with or without 100 µM CK-666 for an 
hour at 37 °C with 5% CO2. The cells were then washed and added to wells of the Boyden 
chamber. MT (10 µM) was used a chemoattractant and the Boyden chamber was incubated for 
3 hours at 37 °C with 5% CO2. Cells that passed through the 5 µm pore membrane were stained 
and enumerated using a microscope. 
Error bars represent standard deviation 
Unpaired t test  (***: p < 0.05) 
Data representative of 3 separate experiments. 
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5.6.2 Phospholipase C (PLC) 
	  
In T lymphocytes, G- protein coupled receptor subunit, Gαi has been shown to activate 
phospholipase C (PLC) β and phosphoinositol-3-kinase (PI3K) γ leading to the modification of 
phospholipids produced by Phosphatidylinositol 4,5-bisphosphate (PIP2). The hydrolysis of 
PIP2 then leads to generation of 1,4,5-triphosphate (IP3) causing an increase in intracellular 
calcium [339].  To test whether this component of calcium signaling is implicated in the MT 
mediated chemotactic response in Jurkat T cells, a small molecule inhibitor 1-[6-[[(17β)-3-
Methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]-1H-pyrrole-2,5-dione (U73122) was used. 
U73122 decreases the availability of PIP2, which is the substrate of the PLC signal 
transduction pathway and can thus block the PLC mediated signaling cascade [340].  
 
Blockade of GPCR signaling cascade by U73122 (PLC inhibitor)  
PLC has been shown to be an important signaling cascade in the chemotactic response 
towards SDF-1 α in lymphocytes [339]. Jurkat T cells were treated with a range of 
concentration of U73122 and the chemotactic response towards SDF-1 α was determined using 
the Boyden chamber assay. The treatment of Jurkat T cells with U73122 at non-toxic 
concentration 1µM significantly reduced the chemotactic response to SDF-1 α and was thus 
used as optimum concentration of the inhibitor for future experiments (data not shown). To 
investigate whether PLC is involved in MT mediated chemotactic response, Jurkat T cells were 
treated with or without 1 µM U73122 for an hour and the chemotactic response to MT was 
measured by Boyden chamber assay. The treatment of cells with U73122 caused a significant 
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inhibition of chemotaxis towards MT suggesting that PLC is involved in the MT mediated 
chemotactic response (Figure 5.6.2). 
 
A.  
 
B. 
 
Figure 5.6.2 
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C. 
 
Figure 5.6.2. Blockade of GPCR signaling cascade by U73122 (PLC inhibitor) inhibits 
MT chemotaxis A. Structure of U73122, a small molecule inhibitor of PLC (Enzo life 
Sciences) 
B. Viability test for U73122 using trypan blue exclusion assay 
C. Jurkat T cells at 2x106 cells/ml were pre-incubated with or without 1µM U73122 for an hour 
37 °C with 5% CO2. The cells were then washed and added to wells of the Boyden chamber 
assay. MT (10 µM) was used a chemoattractant and the Boyden chamber was incubated for 3 
hours at 37 °C with 5% CO2. Cells that passed through the 5 µm pore membrane were stained 
and enumerated using a microscope. 
Error bars represent standard deviation 
Unpaired t test  (****: p < 0.05) 
Data representative of 3 separate experiments. 
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5.6.3 Extracellular signal regulated kinase (ERK) 
	   	  
The extracellular signal regulated kinase (ERK) signaling cascade is a component of 
the mitogen activated protein kinase (MAPK) pathway that is involved in several cellular 
processes such as proliferation, differentiation, development, learning, survival, etc. ERK 
signaling is mediated by small G proteins (RAS) which can lead to activation of a mitogen-
activated protein kinase kinase kinase (MAPKKK) such as BRAF that can further facilitate 
phosphorylation of the second protein kinase in the cascade, MAPKK (MEK). MEKs act as 
dual specificity kinases and activate ERK by phosphorylating the regulatory Tyr and Thr 
residues [341]. 
Effect of MT on ERK signaling 
 To further understand the cell signaling events mediated by MT, we investigated 
whether MT could activate MAP kinase ERK 1/2. Jurkat T cells were stimulated with MT 
(10µM) for different time points along with SDF 1-α (12.5 nM) and Phorbol 1- Myristate 13- 
Acetate (PMA, 325 nM). After stimulation, the cells were fixed and permeabilized and stained 
for phosphorylated ERK1/2 and analyzed by flow cytometer. As expected, there was activation 
of ERK1/2 after stimulation with PMA and SDF 1-α at both 2 minutes and 5 minutes 
timepoints as shown by the increased phosphorylated ERK1/2 staining. Interestingly, MT 
stimulation led to activation of ERK1/2 at only at the 2 minutes timepoint and this activation 
dissipated in later timepoint (Figure 5.6.3.1). 
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A. 
 
 
 
Figure: 5.6.3.1 
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B. 
 
C. 
 
Figure: 5.6.3.1 
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Figure: 5.6.3.1 MT can stimulate ERK1/2: Jurkat T cells at 5x 105 cells/ condition were 
treated with or without MT (10 µM), SDF 1 α (12.5 nM) and PMA (325 nM) for 2 minutes (B) 
and 5 minutes (C) at 37°C. The cells were then fixed, permeabilized and incubated with anti 
human phospho ERK 1/2 antibody for 45 minutes on ice. Intracellular phospho ERK 1/2 was 
detected by anti mIgG-FITC antibody using the LSR/Fortessa X-20 Cell Analyzer illustrated 
by dot plots (A) and histograms (B) and (C).  
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Blockade of ERK signaling cascade by PD98059 (MEK inhibitor)  
PD98059 is a flavonoid that binds to the inactive forms of MEK1 and MEK2 and 
prevents activation by upstream activators such as RAF, which in turn inhibits the activation of 
ERK by MEK. To investigate whether ERK is involved in MT mediated chemotactic response, 
Jurkat T cells were treated with or without 20 µM PD98059 for an hour and the chemotactic 
response to MT was measured by Boyden chamber assay. The treatment of cells with PD98059 
did not affect the chemotactic response of Jurkat T cells towards MT (Figure 5.6.3.2). 
 
A. 
 
Figure 5.6.3.2 
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B. 
 
 
C. 
 
Figure 5.6.3.2 
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Figure 5.6.3.2 Blockade of GPCR signaling cascade by PD98059 (MEK inhibitor) does 
not affect MT chemotaxis A. Structure of PD98059, a small molecule inhibitor of MEK (Cell 
signaling) 
B. B. Viability test for PD98059 using trypan blue exclusion assay 
C. Jurkat T cells at 2x106 cells/ml were pre-incubated with or without 20 µM PD98059 for an 
hour 37 °C with 5% CO2. The cells were then washed and added to wells of the Boyden 
chamber assay. MT (10 µM) was used a chemoattractant and the Boyden chamber was 
incubated for 3 hours at 37 °C with 5% CO2. Cells that passed through the 5 µm pore 
membrane were stained and enumerated using a microscope. 
Error bars represent standard deviation 
Data representative of 3 separate experiments 
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5.6.4 Effect of MT on CXCR4 internalization 
	  
 As mentioned previously, GPCR mediated chemotaxis that results from ligand- 
receptor interaction can lead to receptor internalization and recycling. In order to understand if 
the MT interference of SDF-1 α mediated chemotaxis affects CXCR4 internalization, we used 
flow cytometry analysis to compare the surface expression of CXCR4 in cells with and without 
MT pre-incubation. Jurkat T cells were treated with or without MT, SDF-1 α or a combination 
of both for 30 minutes and then exposed to 12.5 nM SDF-1 α. The cells were then fixed and 
the surface expression of CXCR4 was measured with anti human CXCR4 antibody. CXCR4 
present on the surface of Jurkat T cells were detected by anti mIgG-FITC antibody using the 
LSRFortessa X-20 Cell Analyzer. As seen in Figure 5.3.4 there was reduction in CXCR4 
expression on the surface of Jurkat T cells after addition of SDF-1 α, whereas there was no 
change in CXCR4 expression by MT alone. Additionally, pre-incubation of Jurkat T cells with 
MT before addition of SDF-1 α did not prevent the reduction in CXCR4 expression on the 
surface of cells. Similar experiments were done for 20 minutes time point and an hour time 
point. At none of the time points, MT interfered with the internalization of receptor CXCR4 
(data not shown). 
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A. 
 
B. 
 
 
Figure 5.6.4. 
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Fig 5.6.4. MT does not interfere with CXCR4 internalization: Jurkat T cells (5 x 105/ 
condition) were treated with or without MT (10 µM) and/ or SDF 1 α (12.5 nM) for 30 minutes 
at 37 °C. The cells were then washed and cells were than incubated with anti human CXCR4 
antibody for 45 minutes on ice. CXCR4 surface expression was detected by anti mIgG-FITC 
antibody using the LSRFortessa X-20 Cell Analyzer represented by histogram (A) and bar 
graph (B). 
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5.7 Conclusions 
	  
Despite several evidences documenting MT binding to the surface of lymphocytes, the 
receptor of MT is not fully understood. Here we have shown that AMD3100, which is a 
specific antagonist of CXCR4, can interfere with MT binding to the surface of Jurkat T cells. 
This result suggests that CXCR4 is the receptor that MT binds to on the surface of Jurkat T 
cells. Additionally, when Jurkat T cells were treated with AMD3100, there was a significant 
reduction in the chemotactic response towards MT suggesting that MT mediated chemotactic 
response is via receptor CXCR4. 
 The MT peptide studies indicate that the N- terminal region of MT is responsible for 
interaction with receptor on the surface of Jurkat T cells as pre-incubation with peptides MT1-10 
and MT4-12 can diminish the chemotactic response to SDF-1 α. This is consistent with other 
studies, which have highlighted that N terminus of ligand interacts with the receptor ligand 
binding pocket (chemokine recognition site 2) [232]. Structural comparison between MT and 
chemokine C-X-C as shown in Figure 5.7 highlight shared motifs such as the extended N-
terminus, CXC motif and the basic charged patches that are thought to be responsible for 
chemokine/receptor interactions are also present in MT. 
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Figure 5.7. Comparison of CXC chemokine and MT motif. Adapted from [232]	  
	  
Chemokine receptor interaction can lead to a complex cascade of events that include 
several signaling molecules. The GPCR- chemokine signaling cascades have been 
characterized for different chemokines and their receptors and there are some of the 
components of the signaling cascade that can be variable depending of the chemokine/ ligand 
as well as cell type. Based on our results that hinted towards MT’s possible interaction with 
CXCR4, these studies focused on one cell type (Jurkat T cells) to understand the potential 
signaling components of MT mediated chemotactic response. 
 Here we have shown that MT’s role in regulation of ROS doesn’t influence MT 
mediated chemotactic response as there was no change in intracellular ROS production after 
stimulation with MT. Additionally, the inhibition of chemotactic response towards SDF-1 α 
was not affected by 2-ME alone or MT with 2-ME suggesting that the inhibitory effect of MT 
does not involve its anti-oxidant property.  
KXXK 
KK 
N-terminus 
CXC 
•  MT#has#the#same#conserved#mo0fs#as# the#chemokine# families#
…#CXC#and#the#KXXK#mo0fs.#Both#cri0cal#for#receptor#binding.##
•  Examina0on# of# MT# structure# suggests# that# it# could# mirror# a#
shape#similar# to#chemokines.#Extended#NAterminus,#CXC#mo0f#
and#the#basic#charged#patches# (really#a#basic#plaEorm#region)#
that#are#cri0cal#to#receptor#recogni0on.###
#
•  Comparison# of# this# crystal# structure#with#MT#NMR# structures#
shows# the# NAterminal# residues# can# adopt# an# extended#
conforma0on.###
Basic 
Patch 
Basic 
Patch 
MT1         MDPNCSCSTGGSCTCTSSCACKNCKCTSCKKSCCSCCPVGCSKCAQGCVCKGAADKCTCC 
SDF-1a     KPVSLSYRCPCRFFESHIARANV….KHLKILNTPNCALQIVARLKNNNRQVCIDPKLKWIQEYLEKALNKRLKM 
  
  
MT1        MDPN CSCSTGGSCTCTSSCAC.KNCKCTSC.KKSCCSCCPVGCSKCAQGCVCKGAADKCTCC 
MCP-1   QPDAVNAPLTCCYSFTSKMIPMSRLESYKRITSSRCPKEAVVFVTKLKREVCADPKKEWVQTYIKNLDR 
  
  
MT1                  MDPNCSCSTGGSCTCTSSCACKNCKCTSCKKSCCSCCPVGCSKCAQGCVCKGAADKCTCC 
IL-8    AVLNLGIFVRPCDTQELRCLCIQEHSEFIPL……….KLIKNIMVIFETIYCNRKEVIAVPKNGSMICLDPDAPWVK 
  (only N-terminus of IL-8) 
  
  
MT1       MDPN CSCSTGGSCTCTSSCAC……………………………………………KNCKCTSCKKSCCSCCPVGCSKCAQGCVCKGAADKCTCC 
vMIP-II          LGASWHRPDKCCLGYQKRPLPQVLLSSWYPTSQLCSKPGVIFLTKRGRQVCADKSKDWVKKLMQQLPVTAR  
Hypothesis: MT as Chemokine Mimic 
CXC Chemokine MT (PDB 4MT2) 
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 Our results also indicate that MT mediated chemotactic response involves components 
of GPCR signaling. These results are consistent with earlier studies, which showed that GPCR 
antagonist such as Cholera toxin and Pertussis toxin blocked the MT mediated chemotactic 
response. The use of inhibitors for Arp 2/3 and Phospholipase C significantly inhibited the 
chemotactic response to MT. These results suggest that Arp 2/3 and Phospholipase C, which 
have been implicated in signaling cascades of various chemokines and their receptor, play 
important roles in MT mediated chemotactic response.  
ERK1/2 is a signaling molecule that has been implicated in several cellular processes 
such as proliferation, gene expression, differentiation, mitosis, chemotaxis, etc [342]. We have 
shown that stimulation of Jurkat T cells with MT leads to activation of ERK1/2. Interestingly, 
inhibition of ERK1/2 by a MEK inhibitor did not affect MT chemotaxis. This suggests that MT 
can lead to ERK1/2 activation but this signaling molecule is not involved in the chemotactic 
response.  Further studies are required to investigate the specific role of ERK 1/2 in other 
components of MT function such as proliferation.  
 As mentioned previously, receptor internalization is a component of receptor 
desensitization process that leads to termination of receptor signaling. The recycling of CXCR4 
following SDF stimulation has been shown to be poor leading to lysosomal mediated receptor 
degradation [317]. Our results show that there is no significant decrease in CXCR4 expression 
following MT stimulation suggesting that MT mediated CXCR4 internalization might be 
followed by immediate receptor recycling leading to continuous stimulation of signal 
propagation. 
 In summary, these results indicate that MT mediated chemotactic response involves 
receptor CXCR4 and specific components of GPCR mediated intracellular signaling cascades.  
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Chapter 6: UC1MT as a therapeutic in Type 1 diabetes 
 
Type 1 diabetes 
 Type 1 diabetes (T1D) is an autoimmune disease resulting from the destruction of 
insulin- producing β cells in the pancreas by CD4+ and CD8+ T cells and macrophages 
infiltrating the islets. This destruction leads to insulin deficiency and hyperglycemia [343]. 
According to the Juvenile Diabetes Research Foundation (JDRF), about three million 
Americans have T1D. About 40,000 people are diagnosed each year and approximately 15 
percent of Americans with T1D are children.  
 
Pathogenesis of T1D 
 The cause of T1D is still not fully understood. However, there are four main factors that 
have been associated with the pathogenesis of T1D: genetic, environmental, epigenetic, and 
immunologic related. The main genes predisposing to T1D are within the major 
histocompatibility complex (MHC) region, called HLA (human leucocyte antigen) that are 
located on chromosome 6. Additionally, other regions such as regions coding for the insulin 
gene (Ins-VNTR, IDDM 2), interleukin-2 receptor α, cytotoxic T lymphocyte antigen 4, 
protein tyrosine phosphatase, etc. have also been associated with the disease. The monozygotic 
concordance for T1D is only about 50% highlighting a possible role of environmental factors 
in modulation of genetic susceptibility. Nonobsese diabetic (NOD) mice that lack segmented 
filamentous bacteria are more susceptible to T1D and certain species of bacteria have been 
shown to confer protection from developing the disease. The microbiota of children with T1D 
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was found to be significantly different from the healthy control. Other environmental factors 
such as climate and nutrition has also been suggested to influence T1D [344]. Different viruses 
and vaccinations have been shown to be triggers for T1D. For example, children exposed 
during fetal life to rubella have an increased incidence of T1D. Furthermore, viral capsid 
proteins and other markers of viral infections were found in patients with recent onset of T1D 
[345].  
 Several immune mechanisms related to β cell destruction are well documented. Events 
such as viral infections can lead to increased expression of MHC Class I on β cells and 
production of proinflammatory cytokines such as type I interferon. These proinflammatory 
cytokines can activate the resident dendritic cells, which in turn activate the CD4+ T cells. This 
can lead to macrophage-mediated killing via cytokines and reactive oxygen species. The anti β 
cell immune response is further enhanced by activation of islet antigen specific B cells by 
CD4+ T cells that differentiate into antibody producing plasma cells that mediate complement 
killing. The β cell antigen specific CD4+ T cell and the proinflammatory cytokines can lead to 
cross presentation of antigen to CD8+ T cells, which can also mediate β cell destruction by 
releasing cytolytic granules. IL-4 producing natural killer T (NKT) cells and Tregs have been 
shown to regulate these above-mentioned mechanisms, which can be blocked by production of 
cytokines such as IL-21 [344].  
 
Nonobese diabetes mouse model 
 There are two main mouse models that are used to study type 1 diabetes: NOD mouse 
and bio-breeding (BB) rat model. Both of these models share many of the proposed 
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susceptibility genes for T1D and exhibit humoral and cellular response along with symptoms 
such polyuria, glycosuria, weight loss and lymphocytic infiltration of the islets of Langerhans 
within the pancreas associated with T1D [346, 347]. The NOD mouse model originated in the 
inbreeding of the Cataract Shionogi (CTS) strain in the 1980s and is favored over the BB rat 
model as it provides a better option to study the natural development of diabetogenic T cells. 
The NOD mice spontaneously develop T1D by 30 weeks and the prevalence is much higher in 
female (90%) to males (52%) [347]. The onset of diabetes is marked by moderate glycosouria 
and by non-fasting plasma glucose higher than 250 mg/dl. The susceptibility of T1D in NOD 
mice is mainly due to the unique MHC haplotype (H2g7 = Kd, Aad, Abg7, Enull, Db). 
Additionally, immune abnormalities such as defects in antigen presenting cells, regulation of 
the T lymphocyte repertoire, NK cell function, cytokine production from macrophages are also 
seen in the NOD mouse model [348].	  	  
 
Chemokines and T1D 
 There are several chemokines that have been implicated in type 1 diabetes. Sarkar et al. 
reported CCL5, CCL8, CCL22, CXCL9, CXCL10, and CX3CL1 as the major chemokines that 
were translated by human islet cells in response to inflammatory stimulus in vitro. 
Additionally, CXCL10 was the major chemokine that was expressed in prediabetic animals as 
well as T1D patients [349].  
 CXCR4/ SDF-1 has been shown to be important for human fetal β-cell development 
and differentiation. Additionally, SDF-1 via activation of Akt can provide anti-apoptotic and 
anti-necrotic protection to β-cells from diabetogenic agents [350]. There some conflicting 
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reports on the role of SDF-1 and CXCR4 in T1D pathogenesis. Some studies have suggested 
that neutralization of SDF-1 can inhibit insulitis and progression of diabetes [351]. On the 
contrary, SDF-1 mediated recruitment of T cells was shown to confer protection to recipient 
mice from the adaptive cell transfer of diabetes. The adoptive T cells transfer from mice that 
received AMD3100 (specific CXCR4 antagonist) treatment resulted in decreased prevalence of 
T1D in recipient mice [352]. 
 
MT and T1D 
Gene expression analysis in the pancreas of control mice (NOD, NOD.Scid), insulitis 
mice (BDC2.5NOD) and insulitis and diabetes mice (BDC2.5NOD.Scid) revealed that there is 
an increased expression of three isoforms of MT (Mt1, Mt2 and Mt3) in NOD diabetes and 
insulitis mice [353]. Additionally, transcription profiling of human pancreas from patients with 
type 1 diabetes at different stages of T1D development showed that there was increase in 
expression of MT1 and MT3 isoforms in patients with longstanding T1D compared to control 
patients and patients with early onset of the disease [354]. 
Due to the evidence of increased MT expression in NOD mice as well as patient 
samples and role of MT in chemotaxis of immune and in pathogenesis of inflammatory 
diseases such as IBD, we hypothesized that manipulations on MT can affect the progression of 
T1D. This study was a collaborative work between Dr. Michael A. Lynes at the University of 
Connecticut and Dr. Yu-Hua Tseng and Dr. Matthew D. Lynes at the Joslin Diabetes Center, 
Harvard Medical School, Boston, Massachusetts, and USA. 
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UC1MT treatment for NOD mice 
Treatment regiment 1:   
NOD female mice were divided into two treatment groups with 10 mice in each group: 
UC1MT (monoclonal antibody against MT) and MOPC21.  MOPC21 was used as an isotype 
control for these studies. Mice at 5 weeks of age received IP injections of either 0.1 mg/mouse 
UC1MT or MOPC21 daily and the blood glucose level was monitored twice a week. 8 out of 
the 10 mice in the MOPC21 treatment group developed T1D as noted by the sharp increase in 
blood sugar level. Only 2 out of the 10 mice in UC1MT treatment group developed T1D 
(Figure 6.1). 
  
A. 
 
Figure 6.1 
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B. 
 
Figure 6.1. UC1MT treatment prevents the T1D development in NOD mice: 
A. Schematic representation of the MOPC21 and UC1MT treatment regiment 1 
B. Blood glucose level in mice over 30 weeks time course after receiving daily intraperitoneal 
injection or UC1MT or MOPC21, 100 µl per mouse for two weeks. The concentration of 
all antibodies was at 1 mg/ml. The blood glucose level was checked weekly and the mice 
were sacrificed if they had developed diabetes. All mice in the treatment group were 
sacrificed at the end of 30-week time point. 
(Data: personal communication M.D. Lynes, 2018) 
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Treatment regiment 2:   
NOD female mice were divided into two treatment groups with 10 mice each: UC1MT 
and MOPC21 to study different stages of disease progression.  Mice at 5 weeks of age received 
IP injections of either 0.1 mg/mouse UC1MT or MOPC21 twice a week with the blood glucose 
level monitoring. After 3 weeks, 5 mice in each treatment group were sacrificed for 
histological analysis (time point 1).  The remaining mice, 5 in each treatment group, continued 
to receive IP injections of either 0.1 mg/mouse UC1MT or MOPC21 twice a week with the 
blood glucose level monitoring (time point 2). During time point 1, there was no difference in 
blood glucose level between the two-treatment groups (Figure 6.2 B). During the second time 
point, 3 out of the 5 mice in the MOPC21 treatment group developed T1D as noted by the 
sharp increase in blood sugar level whereas none of the mice in UC1MT treatment group 
developed T1D (Only 2 out of the 10 mice in UC1MT treatment group developed T1D (Figure 
6.2 C). Additional experiments were done to investigate the insulitis score for each treatment 
group. As seen in Figure 6.2 D, the mice that received MOPC21 treatment had much higher 
insulitis score than the ones that received UC1MT treatment. 
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B. 
 
Figure 6.2 
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Figure 6.2. UC1MT treatment prevents the T1D development in NOD mice: 
A. Schematic representation of the MOPC21 and UC1MT treatment regiment 2 
B. Blood glucose level in mice over 3 weeks time course after receiving intraperitoneal 
injection or UC1MT or MOPC21, 100 µl per mouse for twice a week. The concentration of 
all antibodies was given at 1 mg/ml. The blood glucose level was checked weekly and the 
mice were sacrificed if they had developed diabetes. All mice in the treatment group were 
scarificed at the end of 3 timepoint 
C. Blood glucose level in mice over 6 weeks time course after receiving intraperitoneal 
injection or UC1MT or MOPC21, 100 µl per mouse for twice a week. The concentration of 
all antibodies was given at 1 mg/ml. The blood glucose level was checked weekly and the 
mice were sacrificed if they had developed diabetes. All mice in the treatment group were 
scarificed at the end of 6-weeks timepoint 
D. Insulitis score of 20 islets in each treatment group  
(Data: personal communication M.D. Lynes, 2018) 
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Conclusions: 
 Hallmarks of endoplasmic reticulum (ER) stress have been linked to defects in insulin 
secretion and the death of the beta cell before the onset of T1D [355]. Additionally, pro-
inflammatory cytokines such as interleukin -1 beta (IL-1b), interferon gamma (IFNγ) have also 
been implicated in the pathogenesis of T1D [356].  
The preliminary results of this study suggest that the progression of T1D in NOD mice 
can be altered by manipulation of MT. There is a decreased incidence and severity of T1D in 
mice that received UC1MT treatment compared to the MOPC21 controls. UC1MT has also 
been used as a therapeutic in a Dextran Sodium Sulfate (DSS)- induced model of Inflammatory 
Bowel disease. There was a higher survival rate in MT-KO mice, which was associated with 
less severe colonic inflammation as demonstrated by reduced weight loss, decreased histologic 
inflammation and less colon shortening. Additionally, the mice that received the UC1MT 
treatment had a higher survival rate along with less inflammatory cell infiltrate in DSS- 
induced colitis as well trinitrobenzene sulfonic acid (TNBS)- induced colitis model 
highlighting the chemotactic role of MT at sites of inflammation [134].  
As mentioned previously, MT is a stress response protein that is synthesized by cells 
exposed to different forms of stress including proinflammatory cytokines, which can be 
released into the extracellular environment. The up regulation of MT under those conditions 
can lead to increased pro-inflammatory effects and progressive inflammation leading to a 
positive feedback cycle of inflammation, MT synthesis and release. The chemotactic responses 
to the resulting MT gradient can produce an ongoing leukocyte influx and inflammation. 
Blockade of MT under these conditions by UC1MT can hinder the positive feedback loop of 
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MT synthesis leading to abrogation of the pro-inflammatory effect and possibly the 
progression and severity of diseases such as T1D.  
    	  
Conclusions and future directions 
 
Metallothionein (MT) is a stress response protein with unique biochemistry that is 
synthesized by cells exposed to any of the different forms of stress. The role of MT in the 
intracellular environment has been the focus of most of the research on this protein. This study 
focused on the role of MT in the extracellular environment specifically its role in chemotaxis.  
The expression of MT is up regulated by stressful conditions such as exposure to heavy 
metals, acute phase cytokines, glucocorticoids and oxidative stress [3]. MT was detected in the 
cell culture supernatant of Jurkat T cells after stimulation with cadmium chloride. Additionally, 
the secreted protein was also detected on the surface of Jurkat T cells. MT lacks the signal 
peptide sequence that direct protein towards the conventional ER- Golgi pathway suggesting 
that MT secretion might be mediated via the unconventional protein secretion. MT was not 
detected in exosomes isolated from Jurkat T cell culture supernatant following cadmium 
stimulation, which indicates that MT is not secreted by exosome mediated UPS pathway used 
by other stress response protein including Hsp70. Further investigation on the other UPS such 
as heterologous pore formation in the plasma membrane and exovesicular membrane blebbing 
might elucidate the pathway of MT secretion.  
Immune cells respond to chemotactic signals produced by infectious organisms or cells 
at the site of inflammation to mount an immune response. MT secreted to the extracellular 
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environment following stress can act as a chemoattractant for several different cell types such 
as lymphocytes, macrophages, monocytes and primary splenocytes. Additionally, MT can also 
interfere with the chemotactic response of chemokines SDF-1 α, CCL2 and RANTES, which 
represent C-X-C and C-C family of chemokines.  
CXCR4 antagonist AMD3100 can block the binding of MT to the surface of Jurkat T 
cells along with the chemotactic response towards MT suggesting that the protein interacts 
with receptor CXCR4. While some membrane receptors of MT have been proposed [291, 292], 
identification of CXCR4 as a possible receptor for MT is a novel discovery. The N- terminal 
region of MT appears to be responsible for its interaction with the receptor as indicated by the 
MT peptides data, consistent with other chemokine- receptor interaction studies that have 
highlighted the importance of ligand’s N terminal region in receptor recognition and activation 
[232]. To further understand this interaction, additional studies can be done designing mutant 
pairs of cysteines residues in CXCR4 as well as MT peptides similar to those used in CXCR4-
vMIPII structural analysis [357].  
Other studies have shown that Jurkat T cells can bind both isoforms of SDF-1 with high 
affinity. Approximately 150,000 SDF-1α-binding sites were reported per cell with dissociation 
constant (Kd ) between 5 nM and 10 nM [358]. To better understand the binding affinity of MT 
with receptor CXCR4 compared to SDF-1 α, competitive binding assay as described by Hatse 
et al. can be done [359]. Briefly, Jurkat T cells are incubated with Alexa Fluor 647 labeled 
SDF-1 along with varying concentrations of MT and the amount of SDF-1 bound to CXCR4 is 
measured using the flow cytometer. The percentage of inhibition of SDF-1 binding can be 
calculated using the mean fluorescence intensity in the presence of MT at different 
concentrations.  
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Surface plasmon resonance (SPR) is a commonly used technology that is used to 
measure the binding affinity, rate of association and rate of dissociation of GPCRs and their 
ligands. These parameters are calculated based on the change in refractive index at the surface 
of the gold film of an SPR chip, which corresponds to an increase in signal intensity as a result 
of interaction between the ligand and the immobilized receptor [360]. The affinity of MT 
binding to receptor CXCR4 can be determined by using this technology as described by 
Patching et al [361]. Anti- CXCR4 antibody is used to capture detergent solubilized CXCR4 on 
a sensor chip. The captured CXCR4 is then reconstituted in a lipid bilayer by injecting lipid/ 
detergent- mixed micelles. After washing off the detergent molecule, known concentration of 
MT can be circulated over the immobilized and reconstituted CXCR4 and the binding affinity 
can be calculated.  
This study focused on one specific cell type for receptor studies. In future, this can be 
expanded to multiple cell types as well as different receptors as MT mediated chemotactic 
response was not specific for one cell type or a receptor. One of the techniques that can be used 
to study interaction with GPCRs is “The Tango GPCR assay system”. This assay uses a beta-
lactamase reporter construct, which can be activated by the transcription factor tethered to the 
GPCR of interest. The interaction of ligand with the GPCR stimulates recruitment of arrestin 
protease, which triggers release of a tethered transcription factor that can then activate the beta-
lactamase reporter (Thermo Scientific).   
GPCR antagonists such as Cholera toxin and Pertussis toxin can block the chemotactic 
response of MT suggesting a role of GPCR in MT mediated chemotactic response. Specific 
inhibitors for signaling molecules Arp 2/3 and PLC, which are components of GPCR signaling 
cascade, significantly diminished the chemotactic response of Jurkat T cells towards MT 
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validating the involvement of GPCR in MT’s chemotactic response. The signaling cascade 
involved in a chemotactic response is complex and thus additional studies need to be done to 
better understand the other signaling components of this pathway. 
The extracellular pool of MT is used an indicator of stress and can act as a pro 
inflammatory mediator. Manipulation of the extracellular pool of MT has been shown to play 
an important role in the regulation of different inflammatory diseases. For example, targeted 
disruptions of the Mt1 and Mt2 genes in mice have been found to exacerbate chronic 
inflammatory disease and these mice have an increased susceptibility to effects of toxicants 
[25]. The susceptibility to collagen-induced arthritis was shown be decreased by administration 
of MT [14]. Intriguingly, targeted disruptions of the Mt1 and Mt2 genes are also associated 
with the constitutive activation of NF-kB [6], and an enhanced humoral response. As 
mentioned previously, genetic manipulation of MT as well as therapeutic administration of a 
monoclonal anti-metallothionein antibody can decrease the progression of dextran sodium 
sulfate (DSS)-induced inflammatory bowel disease [134]. Similarly, genetic Mt1 and Mt2 
deletion was shown to have beneficial effects in an Alzheimer’s disease model [362, 363], 
TNF-induced lethal shock model [364], and in hyperoxic acute lung injury [365]. These 
examples highlight the contrasting roles of MT under different disease conditions.  
Several studies have highlighted the regulation of chemokines and their receptors 
during development and the establishment of immune response. Impairment in this regulation 
can lead to development and progression of several autoimmune, inflammatory disorders as 
well as cancer progression. For example, a Genome Wide Association Study has shown that 
chemokine receptors are implicated in 12 immune-related disorders, 14 types of cancer, and 
HIV susceptibility and progression [366]. There have been suggestions of several chemokine 
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target therapies but the antagonizing of chemokine receptor has been found to be challenging. 
Hence, finding new avenues to interrupt the interaction between chemokine and their receptors 
might provide new avenues for therapeutic intervention. 
The preliminary findings of this study show that the progression of type 1 diabetes in 
NOD mice can be altered by manipulation of extracellular MT by administration of the 
monoclonal antibody UC1MT. MT released by cells under stress can act as a “danger signal” 
that can lead to an influx of inflammatory cells and the persistence of such signal may lead to 
chronic inflammatory disease. The targeting of extracellular MT using the monoclonal 
antibody will circumvent the potential off target effects that are the major concern for most of 
the anti-inflammatory therapeutics that are currently being administered. The intracellular MT 
will remain inaccessible to the antibody and thus the essential functions of the protein will 
remain unaffected. The role of MT in chemotaxis is a novel area of MT research and the 
identification and better understanding of MT and the potential chemokine receptors in the 
context of different diseases can provide new targets for therapeutics therapeutic intervention. 
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